⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Myasthenia gravis is treatable, and the outlook has been transformed. MG is a chronic autoimmune condition in which the immune system attacks the connection between nerves and muscles, causing weakness that worsens with activity and improves with rest. It is not curable for most people today, but the vast majority of patients can achieve excellent symptom control with modern therapy — and eight FDA-approved targeted drug products are now available.
Your antibody type shapes your entire treatment plan. Most people with MG have AChR antibodies (~85%). A smaller group has MuSK antibodies (~5–8%), and some are "seronegative." Ask your neurologist which type you have — it determines which medications will work best for you.
Pyridostigmine helps symptoms but does not treat the underlying cause. Pyridostigmine (Mestinon) is usually the first medication prescribed. It improves nerve-muscle communication and can provide meaningful relief, but it does not slow the immune attack itself. Most people will also need immune-directed therapy.
Targeted biologics have replaced the old "prednisone-for-life" approach. FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab) rapidly lower harmful antibodies. Complement inhibitors (eculizumab, ravulizumab, zilucoplan) block the immune cascade that damages the nerve-muscle junction. Inebilizumab (UPLIZNA), approved in December 2025, is the first CD19-targeted B-cell therapy for MG. In May 2026, efgartigimod (Vyvgart) became the first MG biologic approved for all adult patients regardless of antibody status. These drugs can dramatically reduce or eliminate steroid dependence.
Thymectomy is proven to help — even without a thymoma. A landmark trial (MGTX) proved that removing the thymus gland improves outcomes in AChR-positive generalized MG, reducing steroid needs and improving strength over 3+ years. If you have a thymoma (a thymus gland tumor), removal is mandatory.
Certain common medications can dangerously worsen MG. Aminoglycosides, fluoroquinolones, beta-blockers, magnesium sulfate, and several other drugs can trigger severe weakness or crisis. Carry a medication alert card at all times and inform every healthcare provider — including dentists and emergency staff — of your MG diagnosis.
Myasthenic crisis is a medical emergency. If your breathing, swallowing, or speaking worsens rapidly, call emergency services immediately. Crisis can be life-threatening but is treatable with rapid intervention including IVIG or plasma exchange in an ICU setting.
Ask about a clinical trial at every stage. The MG pipeline is exceptionally active — mRNA-based CAR-T therapy, next-generation FcRn inhibitors, and other approaches are in advanced trials. In Utah, the University of Utah Neurosciences Center is the primary center for MG specialist care and trial access.

▼ Collapse

Understanding Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune disorder in which the body's immune system mistakenly attacks the neuromuscular junction — the point where nerves connect to muscles. In a healthy body, a chemical called acetylcholine crosses this junction to tell the muscle to contract. In MG, antibodies block, damage, or destroy the receptors for acetylcholine on the muscle side, making the signal weaker. The result is muscle weakness that worsens with use and improves with rest — MG's hallmark feature.

Approximately 70,000 people in the United States and an estimated 700,000 worldwide live with MG. Prevalence is rising, likely due to improved diagnosis and an aging population. MG has a bimodal age pattern: it tends to appear in younger women (ages 20–40) and older men (ages 60–80), but it can occur at any age, including in children.

The big-picture message. Myasthenia gravis has been fundamentally transformed over the past decade. Patients diagnosed today have access to targeted therapies that were unimaginable even 10 years ago — FcRn inhibitors that rapidly reduce harmful antibodies, complement inhibitors that protect nerve-muscle junctions, a proven surgical option (thymectomy), and now a CD19-targeted B-cell therapy (inebilizumab). The majority of patients with MG can achieve good symptom control and maintain active lives. While MG remains a chronic condition requiring ongoing management, the trajectory has shifted from a disease once considered life-threatening to one where most patients achieve meaningful remission or excellent control with modern therapy.

The types of MG — why your antibody result matters

Not all MG is the same. Your antibody test result is one of the most important pieces of information in your care, because it determines which treatments are most effective:

AChR-antibody positive (~85% of generalized MG) — antibodies target the acetylcholine receptor. This is the most common form. All eight FDA-approved targeted drug products are available for this group.
MuSK-antibody positive (~5–8%) — antibodies target muscle-specific kinase, a protein that helps maintain the receptor cluster. MuSK-MG often causes prominent bulbar weakness (difficulty swallowing, speaking, and facial weakness). Treatment differs significantly — pyridostigmine often does not work well, rituximab is a preferred early biologic, and complement inhibitors are less applicable. As of 2025, rozanolixizumab (Rystiggo), nipocalimab (IMAAVY), and inebilizumab (UPLIZNA) are FDA-approved targeted therapies that also cover MuSK-positive MG.
LRP4-antibody positive (~1–2%) — a rarer antibody target. Testing is not widely available outside research settings.
Seronegative (~5–10%) — standard blood tests do not detect antibodies, but the person clearly has MG based on clinical features and electrophysiology. Some may have antibodies detectable only by specialized assays.

Ocular versus generalized MG

MG also varies in how much of the body it affects:

Ocular MG (MGFA Class I) — weakness affects only the eye muscles, causing drooping eyelids (ptosis) and double vision (diplopia). About 50–60% of people who start with ocular MG will develop generalized weakness within the first two years. Early treatment may reduce this risk.
Generalized MG (MGFA Class II–V) — weakness extends beyond the eyes to limbs, swallowing, breathing, and/or the neck and trunk. Class V indicates myasthenic crisis requiring ventilatory support.

Early-onset, late-onset, and thymoma-associated MG

Neurologists also categorize MG by the age it begins and whether a thymoma is present, because these factors influence prognosis and treatment:

Early-onset MG (before age 50) — more common in women. Often associated with thymic hyperplasia (an enlarged but non-cancerous thymus). Thymectomy can be especially beneficial in this group.
Late-onset MG (after age 50) — more common in men. The thymus is typically atrophied. Late-onset MG is the fastest-growing subgroup, driven by improved recognition in older adults. Elderly patients face higher risks from both the disease (infection-triggered crisis) and its treatment (steroid side effects including osteoporosis, diabetes, and infection; increased infection susceptibility with immunosuppressants). Most targeted biologics are approved for adults only; eculizumab (ages 6+) and nipocalimab (ages 12+) are the only therapies with pediatric approvals.
Thymoma-associated MG — about 10–15% of MG patients have a thymoma (a tumor of the thymus gland). These are usually not aggressive but require surgical removal and ongoing monitoring.

MG often begins subtly. The first sign may be a drooping eyelid, double vision, difficulty chewing tough foods, a voice that becomes nasal or weak during conversation, or unexplained fatigue that worsens as the day goes on. Because symptoms fluctuate — "good days" and "bad days" — many people are initially told nothing is wrong, and diagnosis is often delayed by months or years.

Recognizing MG early matters. Starting treatment before the disease generalizes or before a crisis occurs leads to better long-term outcomes. If you have fluctuating weakness that worsens with activity, ask your primary care provider about MG and request referral to a neurologist — ideally a neuromuscular specialist.

Common first symptoms to watch for:

One or both eyelids drooping (ptosis), often worse in the evening
Double vision (diplopia) that comes and goes
Difficulty chewing — jaw tiring during a meal
Slurred or nasal speech that worsens with prolonged talking
Difficulty swallowing, choking, or food/liquid coming out the nose
Arm or leg weakness that worsens with repeated use (trouble climbing stairs, lifting arms to wash hair)
Shortness of breath, especially when lying down or during exertion
Neck weakness (difficulty holding the head up — "dropped head")

A key feature of MG is that these symptoms worsen with activity and improve with rest. If you notice this pattern, bring it to your doctor's attention.

The Myasthenia Gravis Foundation of America (MGFA) Clinical Classification ranks MG severity. Your doctor may refer to your "MGFA Class":

Class I — eye muscle weakness only (ocular MG)
Class II — mild generalized weakness (IIa = predominantly limb/trunk; IIb = predominantly bulbar — swallowing, speech)
Class III — moderate generalized weakness (IIIa = limb/trunk; IIIb = bulbar)
Class IV — severe generalized weakness
Class V — crisis requiring intubation or mechanical ventilation

Your class can change over time — with treatment, many people improve. Ask your neurologist what your current MGFA Class is and what scores they are using to track your progress (MG-ADL, QMG, or MG Composite).

Which antibody type do I have — AChR, MuSK, LRP4, or seronegative?
Is my MG ocular or generalized, and what is my MGFA Class?
How likely is my ocular MG to become generalized?
What score are you using to track my MG severity, and what is my current number?
Does my chest CT or MRI show a thymoma?
What does my overall outlook look like?
Should I be seen at a specialized neuromuscular center for additional testing or trial options?

Educational use only. This guide explains general concepts. It cannot tell you what is right for your situation. Every decision should be made with your neurologist or neuromuscular specialist, who knows your specific test results, antibody type, health, and preferences.

Genetics & Risk Factors

MG is not a directly inherited disease — you do not "pass it on" like cystic fibrosis or sickle cell disease. However, genetics influence susceptibility. Having a family member with MG slightly increases risk, and certain genetic markers are associated with different MG subtypes:

HLA genes (human leukocyte antigen) — the strongest genetic associations. HLA-B8, HLA-DR3, and HLA-A1 are overrepresented in early-onset AChR-positive MG (particularly in women of European descent). Late-onset MG shows associations with HLA-DR7 and HLA-B7.
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) — variants in this immune-checkpoint gene have been linked to increased MG susceptibility, consistent with its role in other autoimmune diseases (type 1 diabetes, thyroid disease).
PTPN22 — a gene involved in T-cell signaling. The R620W variant is a known risk factor for multiple autoimmune conditions and has been associated with MG in several population studies.
TNFRSF11A (RANK) — associated with thymoma-associated MG and may play a role in thymic pathology.

Risk factors beyond genetics:

Sex and age: women are more commonly affected at younger ages (20–40); men more commonly after age 60. Overall lifetime prevalence is roughly equal between sexes.
Other autoimmune diseases: having one autoimmune condition (thyroid disease, rheumatoid arthritis, lupus, type 1 diabetes) increases the risk of developing MG.
Thymoma: thymic tumors are strongly associated with MG. About 30–50% of people with thymomas develop MG.
Immune checkpoint inhibitor therapy: cancer patients treated with PD-1/PD-L1 or CTLA-4 inhibitors (immunotherapy — ipilimumab, nivolumab, pembrolizumab, and others) can develop de novo MG or experience severe flare of pre-existing MG. Checkpoint inhibitor-induced MG is an increasingly recognized and potentially fatal iatrogenic cause, with mortality rates significantly higher than idiopathic MG. Management requires immediate discontinuation of the checkpoint inhibitor, high-dose corticosteroids, and sometimes PLEX or IVIG. Resumption of checkpoint inhibitor therapy after MG onset is generally not recommended.
D-penicillamine: this drug (used for Wilson disease and rheumatoid arthritis) can induce MG-like antibodies, which usually resolve after the drug is stopped.

For families: the risk of a first-degree relative developing MG is low (estimated 3–5% compared to the general population prevalence of about 20 per 100,000). Congenital myasthenic syndromes — a separate group of genetic (not autoimmune) conditions affecting the neuromuscular junction — are inherited and require different treatment. If multiple family members have neuromuscular weakness, genetic testing for congenital myasthenic syndromes should be considered.

Diagnosis & Classification

Diagnosing MG requires putting together clinical findings, blood tests, and specialized nerve/muscle testing. The diagnosis answers three questions: Is it MG? Which antibody type? How severe is it?

Blood tests — antibody panels

The single most important diagnostic step is antibody testing:

AChR antibody panel (binding, blocking, and modulating antibodies) — positive in about 85% of people with generalized MG and about 50% of those with purely ocular MG.
MuSK antibody — tested if AChR antibodies are negative. A cell-based assay is more sensitive than standard ELISA.
LRP4 antibody — a research-level test, not widely available in routine clinical practice.

If standard antibody tests are negative but your doctor strongly suspects MG, specialized assays (such as clustered AChR antibody testing) may detect antibodies that standard tests miss.

Key diagnostic tests to expect. Antibody blood panel (AChR, and if negative, MuSK); repetitive nerve stimulation (RNS) — an electrodiagnostic test that measures how well the nerve-muscle junction conducts signals (a characteristic "decrement" on RNS supports the diagnosis); single-fiber EMG (SFEMG) — the most sensitive test for MG (>95% sensitivity), detecting subtle transmission failures; CT or MRI of the chest to look for a thymoma; and an ice pack test for ptosis (placing ice on a drooping eyelid for 2 minutes — improvement suggests MG).

Repetitive nerve stimulation (RNS) sends a series of electrical pulses to a nerve while measuring the muscle's response. In MG, the muscle response weakens (decrements) with repeated stimulation — a pattern called a "decremental response." The test is performed on clinically weak muscles and takes about 30–45 minutes. It is uncomfortable but not painful for most people.

Single-fiber EMG (SFEMG) uses a very thin needle to measure individual muscle fibers. It detects "jitter" — variability in the time it takes a nerve signal to reach the muscle. Increased jitter is the most sensitive electrical finding in MG. SFEMG is usually done when RNS and antibody tests are inconclusive.

All people newly diagnosed with MG should have a CT scan (or MRI) of the chest to check for a thymoma — a tumor of the thymus gland. About 10–15% of people with MG have a thymoma, and removing it is mandatory. Even without a thymoma, the thymus is believed to play a role in MG, which is why thymectomy can be beneficial.

Thymomas associated with MG are usually not aggressive cancers, but they do need to be removed and monitored. If a thymoma is found, your care team will include a thoracic surgeon.

Several other conditions can mimic MG symptoms, and your neurologist may test for these:

Lambert-Eaton Myasthenic Syndrome (LEMS) — another autoimmune neuromuscular disorder, often associated with small-cell lung cancer. Unlike MG, strength often improves briefly with repeated use.
Congenital myasthenic syndromes — genetic (not autoimmune) conditions that affect the neuromuscular junction from birth.
Thyroid eye disease — can cause eye muscle problems similar to ocular MG.
Chronic progressive external ophthalmoplegia — a mitochondrial condition affecting eye muscles.

Diagnosing MG can take time, and it is not unusual for the process to span several appointments:

Clinical evaluation — your neurologist will take a detailed history of your symptoms, focusing on the pattern of weakness and whether it fluctuates. They will perform a physical examination testing specific muscle groups.
Blood tests — AChR antibody panel (results in days to a couple of weeks). If negative, MuSK antibody testing is ordered.
Electrodiagnostic tests — repetitive nerve stimulation (RNS) and/or single-fiber EMG (SFEMG) are scheduled, usually within days to weeks. These may be done at your first or second neurology visit.
Chest imaging — a CT scan to check for a thymoma.
Clinical bedside tests — the ice pack test (placing a bag of ice on a drooping eyelid for 2 minutes — improvement suggests MG, about 80% sensitivity) may be done during an office visit.
Additional testing — thyroid function, complete blood count, and other autoimmune markers may be checked, as MG can overlap with other autoimmune conditions (thyroid disease, rheumatoid arthritis, lupus).

If you feel your diagnosis is taking too long, or if standard tests are negative but you are sure something is wrong, ask for referral to a neuromuscular specialist. Specialized tests such as clustered AChR antibody assays can detect antibodies missed by standard panels.

Tracking your severity — the scores your team uses

Your neurologist will use standardized scoring tools at each visit to track your MG objectively:

MG-ADL (Activities of Daily Living) — an 8-item patient-reported questionnaire covering talking, chewing, swallowing, breathing, eye symptoms, and limb function. This is the primary measure used in most clinical trials.
QMG (Quantitative MG) score — a 13-item clinician-scored examination testing specific muscle groups.
MG Composite — a 10-item combined clinician-patient assessment.

Ask your team which score they are tracking and what your current number is. Watching these numbers over time helps you understand whether treatment is working.

Which antibody test was positive (or were they all negative)?
If my standard antibodies are negative, should I be tested with a more specialized assay?
What did my repetitive nerve stimulation or SFEMG show?
Does my chest CT show a thymoma or any thymus abnormality?
What is my MGFA Class and my MG-ADL or QMG score?
How often will my severity be reassessed?
Could any of my other medical conditions or medications be contributing to my symptoms?
Can I get copies of my test results and reports?

Standard Treatment

Treatment for MG is built in layers: symptomatic relief (pyridostigmine), then immune-directed therapy to address the underlying autoimmune attack, and acute rescue treatments when the disease flares. The overarching goal in modern MG care is achieving "minimal manifestation status" — little or no weakness in daily life — with minimal or no prednisone. "Steroid-sparing" is a central principle of today's treatment.

Important context. Pyridostigmine treats symptoms. Everything else in this section and the next treats the immune system itself. Your treatment plan will be tailored to your antibody type (AChR, MuSK, seronegative), your MGFA Class, whether you have a thymoma, your age, other health conditions, reproductive planning, and your preferences.

Pyridostigmine (Mestinon) — symptomatic treatment

Pyridostigmine is usually the first medication prescribed. It works by blocking the enzyme that breaks down acetylcholine, allowing more of this chemical to accumulate at the nerve-muscle junction and strengthening the muscle signal. It treats symptoms but does not slow or stop the immune attack.

How it's taken: oral tablets, typically 3–4 times a day. Timing matters — many people learn to take doses 30–60 minutes before meals or demanding activities.
Common side effects: stomach cramping, diarrhea, increased salivation, sweating. These usually improve as the dose is optimized.
Important note for MuSK-MG: MuSK-positive patients frequently experience severe cholinergic hypersensitivity to pyridostigmine — fasciculations (muscle twitching), cramping, excessive secretions, and paradoxical worsening of weakness. Pyridostigmine must be used with extreme caution or avoided entirely in MuSK-MG. If attempted at all, start at the lowest possible dose under close medical supervision. Most MuSK-MG patients require early transition to immune-directed therapy rather than reliance on pyridostigmine.

Corticosteroids — the traditional immune therapy

Prednisone (or prednisolone) remains the most widely used immunosuppressive medication for MG worldwide. It is effective and relatively fast-acting, but carries significant long-term side effects including weight gain, elevated blood sugar, osteoporosis, cataracts, mood changes, and increased infection risk.

Start "low and slow." In MG, prednisone is typically started at a low dose and increased gradually because rapid high-dose initiation can temporarily worsen MG weakness — this is a unique feature of the disease.
The goal is to get off steroids or minimize them. Almost every modern treatment strategy is designed to reduce or eliminate long-term steroid use ("steroid-sparing").

Conventional immunosuppressants (steroid-sparing agents)

These medications are added to reduce prednisone needs. They take time — often months — to reach full effect:

Azathioprine (Imuran) — the most commonly used steroid-sparing agent worldwide. Takes 6–12 months for full benefit. Requires monitoring of blood counts and liver function. A genetic test (TPMT) should be done before starting.
Mycophenolate mofetil (CellCept) — widely used. Also takes months to work fully. Mixed results in formal trials, but clinical experience supports its value. Carries an FDA Boxed Warning for first-trimester pregnancy loss and congenital malformations (facial clefts, microtia). Must be discontinued at least 6 weeks before conception. Requires dual contraception and enrollment in the Mycophenolate REMS program.
Tacrolimus — may have a faster onset than azathioprine (weeks rather than months). Commonly used in Japan and increasingly worldwide. Requires drug level monitoring.
Cyclosporine — effective but with more side effects (kidney function and blood pressure require monitoring).
Methotrexate — used in some centers as a steroid-sparing option.
Cyclophosphamide — a potent immunosuppressant sometimes used in severe, refractory MG when other options have failed. Carries significant side effects (infection risk, infertility, long-term malignancy risk) and has been largely supplanted by targeted biologics. Used infrequently in modern MG care.
Belimumab (Benlysta) — a BLyS (B-lymphocyte stimulator) inhibitor approved for lupus. Used off-label in some refractory MG cases based on the rationale of reducing B-cell survival. Limited evidence; discussed as an option in treatment-refractory cases.

MG treatment is typically escalated in a stepwise fashion. Understanding this "ladder" helps you know where you are and what comes next:

Step 1 — Symptomatic relief: Pyridostigmine to improve nerve-muscle communication.
Step 2 — Corticosteroids: Prednisone when pyridostigmine alone is insufficient. Started low and increased slowly.
Step 3 — Steroid-sparing agent: Azathioprine, mycophenolate, tacrolimus, or another conventional immunosuppressant added to reduce steroid burden.
Step 4 — Thymectomy: For thymoma (mandatory) or for non-thymomatous AChR+ gMG ages 18–65.
Step 5 — Targeted biologics: FcRn inhibitors, complement inhibitors, or B-cell therapy for patients with inadequate response to conventional therapy or unacceptable steroid dependence.
Rescue at any time: IVIG or plasma exchange for acute flares or crisis.

In practice, not everyone follows this exact sequence. Some patients with severe disease are started on targeted biologics early. Your neurologist will tailor the approach to your specific situation. The trend in modern MG care is toward earlier use of targeted biologics to avoid years of high-dose steroids.

These are used for acute worsening, myasthenic crisis, or as "bridge therapy" (holding the disease stable while waiting for a slower-acting immunosuppressant to take effect, or before surgery):

Intravenous immunoglobulin (IVIG) — a large dose of pooled antibodies given by IV over several days. It modulates the immune system and typically improves symptoms within 1–2 weeks. Effects last about 3–6 weeks. It can also be given subcutaneously (SCIg) for ongoing maintenance.
Plasma exchange (PLEX / plasmapheresis) — physically removes antibodies from the blood. Typically given as 5 exchanges over 10–14 days. Onset is faster than IVIG (often within days). Effects are temporary. PLEX may be preferred over IVIG for MuSK-MG acute flares (MuSK antibodies are IgG4 subclass).

Both are equally effective for crisis. The choice often depends on availability, IV access, and the specific MG subtype.

If your MG is currently limited to the eyes (MGFA Class I), treatment typically starts with pyridostigmine. If that is not enough, low-dose corticosteroids are added. A steroid-sparing agent may be introduced if chronic steroids are needed. Your neurologist will monitor for "secondary generalization" — the spread of weakness beyond the eyes — which occurs in 30–50% of ocular MG patients within the first two years. Some experts favor early immunosuppression in higher-risk patients to try to prevent generalization.

MuSK-antibody-positive MG has a distinct treatment profile that you and your care team need to understand:

Pyridostigmine often provides little benefit and can cause severe cholinergic hypersensitivity (fasciculations, cramping, excessive secretions, paradoxical worsening). Pyridostigmine must be used with extreme caution or avoided entirely in MuSK-MG.
Corticosteroids are used but steroid-sparing is even more important.
Rituximab is increasingly considered the preferred early biologic for MuSK-MG. Although not FDA-approved specifically for MG, multiple studies show 60–80% sustained remission rates in MuSK-positive patients. It depletes CD20+ B cells that produce harmful antibodies.
Rozanolixizumab (Rystiggo), approved June 2023, and nipocalimab (IMAAVY), approved April 29, 2025, are FcRn inhibitors approved for MuSK-positive MG.
Inebilizumab (UPLIZNA), approved December 2025, is a CD19-targeted B-cell therapy approved for both AChR+ and MuSK+ MG.
Complement inhibitors (eculizumab, ravulizumab, zilucoplan) are less applicable for MuSK-MG because MuSK antibodies are IgG4 subclass, which does not efficiently activate the complement system.
Thymectomy is not recommended for MuSK-MG.
For acute flares, plasma exchange (PLEX) is generally preferred over IVIG.

What treatment plan are you recommending for my specific MG subtype and severity?
Is pyridostigmine expected to work well for my type of MG?
Am I going to need prednisone, and if so, what is the plan to reduce or stop it?
Which steroid-sparing medication do you recommend, and how long until it takes full effect?
Should I be considered for a targeted biologic (FcRn inhibitor, complement inhibitor, or B-cell therapy) now, or at what point?
If I have MuSK-MG, is rituximab appropriate for me?
What is the plan if my symptoms worsen suddenly — IVIG or PLEX?
Which side effects should I report immediately?
Are there clinical trials available for my type of MG?

Boxed Warnings & REMS Requirements

Several MG medications carry FDA Boxed Warnings (the most serious safety warnings) and/or require enrollment in a REMS (Risk Evaluation and Mitigation Strategy) program. Understanding these is essential for safe treatment.

⚠ BOXED WARNING: Eculizumab (Soliris) & Ravulizumab (Ultomiris) — Meningococcal Infection

Complement C5 inhibitors increase the risk of serious, potentially fatal meningococcal infections (Neisseria meningitidis). Patients MUST receive meningococcal vaccines (both MenACWY and MenB serogroup B) at least 2 weeks before the first dose. Vaccination lowers but does NOT eliminate risk — life-threatening meningococcal infections can occur even after vaccination. If complement inhibition is needed urgently before the 2-week vaccination window: deliver vaccines immediately and start prophylactic antibiotics — Ciprofloxacin 500 mg once daily, or Penicillin V 250–500 mg twice daily, or Levofloxacin 500 mg once daily — and maintain antibiotic prophylaxis for at least 2 weeks after the final vaccine doses are administered. Patients must be monitored for early signs of meningococcal infection and evaluated immediately if suspected: sudden high fever, severe headache, stiff neck, and/or dark purple rash. Prescribers must be enrolled in the REMS program.

Source: Soliris FDA Label; Ultomiris FDA Label

⚠ BOXED WARNING: Zilucoplan (Zilbrysq) — Meningococcal Infection

As a complement C5 inhibitor, zilucoplan carries the same meningococcal infection risk. The identical vaccination and REMS requirements apply. Despite being a small-molecule subcutaneous injection rather than a monoclonal antibody, the mechanism of complement blockade creates the same infectious risk. All three complement inhibitors share this boxed warning.

Additional warning — pancreatitis (FDA label Section 5.4): Cases of pancreatitis, including serious cases, have been reported with zilucoplan. Advise patients to seek immediate medical attention for severe abdominal pain, especially if accompanied by nausea, vomiting, or fever. Lipase and amylase should be monitored as clinically indicated.

⚠ WARNING: Efgartigimod (Vyvgart / Vyvgart Hytrulo) — Infection Risk

FcRn inhibitors lower total IgG levels, which can reduce the body's ability to fight infections. The prescribing information warns of increased risk of infection, including serious infections. IgG levels should be monitored during treatment, and treatment should be delayed if the patient has an active, serious infection. Patients should report signs of infection promptly. The risk is proportional to the degree of IgG reduction.

⚠ WARNING: Rituximab (Rituxan) — Hepatitis B Reactivation & PML

Hepatitis B reactivation: Rituximab carries a Boxed Warning for hepatitis B virus (HBV) reactivation, which can cause fulminant hepatitis, liver failure, and death. All patients must be screened for HBV (HBsAg and anti-HBc) before starting rituximab. HBV carriers require antiviral prophylaxis and monitoring. Progressive multifocal leukoencephalopathy (PML): Rare cases of JC virus–associated PML have been reported with rituximab, particularly in patients who have received multiple immunosuppressive therapies. PML is often fatal. Report new neurological symptoms immediately.

Note: Rituximab is used off-label for MG but its safety profile from approved indications applies fully.

⚠ WARNING: Inebilizumab (UPLIZNA) — Infection, PML & Infusion Reactions

As a B-cell depleting therapy, inebilizumab increases the risk of infections, including serious and opportunistic infections. Hepatitis B screening is required before starting. Progressive multifocal leukoencephalopathy (PML): consistent with the class risk of B-cell depleting therapies, PML is a potential risk. Report any new or worsening neurological symptoms promptly. Infusion-related reactions can occur, particularly with the first infusion. Premedication with corticosteroids, antihistamines, and antipyretics is recommended.

REMS programs — what patients need to know

All three complement inhibitors (eculizumab, ravulizumab, zilucoplan) require enrollment in a REMS program:

Your prescribing neurologist must be REMS-certified to prescribe these drugs.
The pharmacy dispensing the drug must be REMS-certified.
You (the patient) must be enrolled in the REMS program and receive a Patient Safety Information Card that you carry at all times.
You must be educated about the risk of meningococcal infection, vaccinated before treatment, and able to recognize the signs of meningococcal infection.
If you change pharmacies, infusion centers, or prescribers, REMS enrollment must be re-confirmed.

Your neurology team handles REMS enrollment as part of the prescribing process. The key for you is to carry your Patient Safety Card at all times and seek emergency care immediately for sudden fever, stiff neck, headache, or rash while on a complement inhibitor.

Important Drug Interactions

Beyond the general list of medications that worsen MG, there are specific pharmacologic interactions that patients and caregivers should understand:

Pyridostigmine interactions

Beta-blockers (propranolol, atenolol, metoprolol) — can directly worsen neuromuscular transmission and may mask the cardiac effects of cholinergic excess from pyridostigmine. This combination can reduce the effectiveness of pyridostigmine and simultaneously increase the risk of bradycardia. If a beta-blocker is medically necessary (e.g., for cardiac arrhythmia), careful dose adjustment and monitoring are required.
Corticosteroids — when prednisone is started at high doses in MG patients, it can temporarily worsen weakness in the first 1–2 weeks. Pyridostigmine doses may need to be adjusted during steroid initiation.
Atropine and anticholinergic drugs — these oppose the mechanism of pyridostigmine. Common anticholinergics (diphenhydramine, scopolamine, some bladder medications) can reduce pyridostigmine's effectiveness.

Immunosuppressant interactions

All immunosuppressants + live vaccines — patients on azathioprine, mycophenolate, tacrolimus, cyclosporine, rituximab, inebilizumab, or high-dose corticosteroids should not receive live vaccines (MMR, varicella, live-attenuated influenza nasal spray, yellow fever). Inactivated vaccines are safe and recommended.
Azathioprine + allopurinol — allopurinol (used for gout) dramatically increases azathioprine toxicity by inhibiting its metabolism. This combination requires major dose reduction (typically 75% reduction) or use of an alternative gout medication.
Tacrolimus + CYP3A4 inhibitors/inducers — tacrolimus levels are significantly affected by drugs that inhibit CYP3A4 (ketoconazole, fluconazole, erythromycin, grapefruit juice — increases tacrolimus levels and toxicity) or induce CYP3A4 (rifampin, phenytoin, carbamazepine — decreases tacrolimus levels). Drug level monitoring is essential.
Mycophenolate + antacids/iron — aluminum/magnesium antacids and iron supplements can reduce mycophenolate absorption. Separate dosing by at least 2 hours.

Complement inhibitor interactions

Eculizumab/ravulizumab + meningococcal vaccines — complement blockade may reduce the immune response to meningococcal vaccines. Vaccination at least 2 weeks before starting treatment is strongly preferred. If vaccination occurs after starting treatment, antibody response should be monitored.

FcRn inhibitor interactions

FcRn blockers + IVIG — FcRn inhibitors (Vyvgart, Rystiggo, IMAAVY) accelerate the clearance of all IgG antibodies, including therapeutic IVIG. Concurrent use reduces IVIG efficacy significantly. If both are needed, space them at least 2–3 weeks apart and coordinate timing with your neurology team. Measure IgG levels to confirm adequate IVIG effect before the next FcRn inhibitor cycle.

Critical interaction pairs — quick reference

Drug A	Drug B	Risk	Action Required
FcRn blocker (Vyvgart, Rystiggo, IMAAVY)	IVIG	Accelerates IVIG clearance, reduces efficacy	Space 2–3 weeks apart; monitor IgG levels
Pyridostigmine	Succinylcholine	Prolonged neuromuscular paralysis (pyridostigmine inhibits plasma cholinesterase that metabolizes succinylcholine)	Notify anesthesia team; avoid succinylcholine if possible; use reduced-dose non-depolarizing agents
Azathioprine	Allopurinol	Dramatically increases azathioprine toxicity (xanthine oxidase inhibition blocks metabolism)	Reduce azathioprine dose by 75%; monitor CBC weekly; consider alternative gout therapy

Practical guidance. Keep a complete, current medication list (including supplements, over-the-counter drugs, and herbal products) and share it with every provider who prescribes or dispenses medication. Use one pharmacy whenever possible so the pharmacist can screen for interactions. When in doubt, call your neurology team before starting anything new.

Targeted Biologics & Surgery

The past decade has brought a revolution in MG treatment. Where patients once relied almost exclusively on prednisone and general immunosuppressants, there are now eight FDA-approved targeted drug products that address specific immune pathways. This section covers these newer treatments and thymectomy.

The treatment landscape in June 2026. Eight targeted drug products are now FDA-approved for generalized MG: three FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab), three complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), and one CD19-targeted B-cell therapy (inebilizumab). Thymectomy — a procedure, not a drug — is proven beneficial even without a thymoma. Additionally, rituximab (anti-CD20 B-cell therapy) is widely used off-label, especially for MuSK-MG. As of May 8, 2026, efgartigimod (Vyvgart) became the first MG biologic approved for all adult gMG patients regardless of antibody status — AChR+, MuSK+, LRP4+, and seronegative. This is an unprecedented era of treatment choice.

FcRn inhibitors — rapidly lowering harmful antibodies

FcRn (neonatal Fc receptor) inhibitors work by blocking a receptor that normally recycles IgG antibodies, causing harmful MG antibodies to be cleared from the body faster. They can improve muscle strength within 1–2 weeks and represent a major shift from broad immunosuppression to targeted antibody reduction.

Efgartigimod (Vyvgart / Vyvgart Hytrulo) — FDA-approved December 2021 (IV) and June 2023 (subcutaneous with hyaluronidase for home self-injection). Originally for AChR-positive generalized MG. Supported by the ADAPT trial (68% responder rate vs. 30% placebo). Given as treatment cycles: IV weekly for 4 weeks, then re-treat when symptoms recur. By Argenx. On May 8, 2026, FDA expanded Vyvgart to ALL adult gMG patients regardless of antibody status — AChR+, MuSK+, LRP4+, and seronegative. This is the first MG biologic approved for all serotypes. This expansion was driven by the Phase 3 ADAPT SERON study (NCT06298552), which confirmed significant clinical improvements in patients lacking detectable AChR antibodies.
Rozanolixizumab (Rystiggo) — FDA-approved June 26, 2023. For AChR-positive or MuSK-positive generalized MG. Subcutaneous injection weekly for 6-week treatment cycles. Supported by the MycarinG trial. By UCB.
Nipocalimab (IMAAVY) — FDA-approved April 29, 2025. The broadest indication among FcRn blockers: for both AChR-positive and MuSK-positive generalized MG, in adults and pediatric patients aged 12 and older. This is the first FcRn inhibitor approved for pediatric patients. Available as IV infusion only. Supported by the Vivacity-MG3 Phase 3 trial. By Johnson & Johnson.

Side effects of FcRn inhibitors are generally mild: headache, upper respiratory infections, urinary tract infections. Because they lower total IgG levels (not just the harmful antibodies), infection monitoring is important. Your doctor will monitor your IgG levels and overall infection risk during treatment.

All three FcRn inhibitors work by the same basic mechanism (blocking antibody recycling), but they differ in practical ways that may influence your choice:

Efgartigimod (Vyvgart/Vyvgart Hytrulo): The longest real-world track record (approved since 2021). IV version requires clinic visits; SC version allows home self-injection. Treatment cycles of 4 weekly infusions/injections, then wait and re-treat when symptoms recur. Originally AChR+ only; as of May 8, 2026, expanded to ALL adult gMG regardless of antibody status (the first MG biologic approved for all serotypes).
Rozanolixizumab (Rystiggo): Subcutaneous only (home self-injection). Treatment cycles of 6 weekly injections. AChR+ or MuSK+. The SC-only design may be preferred by people who want to avoid clinic IV infusions entirely.
Nipocalimab (IMAAVY): IV infusion only. The broadest indication — both AChR+ and MuSK+ MG, and ages 12+. Given every 2–4 weeks as ongoing treatment rather than discrete cycles. The only FcRn inhibitor approved for adolescents.

Your neurologist will recommend the FcRn inhibitor that best fits your antibody type, age, severity, lifestyle preferences, and insurance coverage. All three are effective; the differences are mainly in route, schedule, and indication breadth.

Complement inhibitors — blocking the attack on the junction

In AChR-positive MG, the antibodies activate a part of the immune system called the complement cascade, which directly damages the neuromuscular junction. Complement inhibitors block this cascade, protecting the junction from destruction.

Eculizumab (Soliris) — FDA-approved October 2017 for adults with AChR-positive refractory generalized MG. Expanded February 28, 2025 to pediatric patients aged 6 and older — the first treatment approved for pediatric generalized MG. Given by IV every 2 weeks. Supported by the REGAIN trial. By Alexion/AstraZeneca. Biosimilars now available: Bkemv and Epysqli are FDA-approved eculizumab biosimilars with adult AChR+ gMG on their labels, potentially offering significant cost savings.
Ravulizumab (Ultomiris) — FDA-approved April 2022 for AChR-positive generalized MG. A longer-acting version of eculizumab, given by IV every 8 weeks after loading doses — far more convenient. Supported by the CHAMPION-MG trial. By Alexion/AstraZeneca.
Zilucoplan (Zilbrysq) — FDA-approved October 2023 for AChR-positive generalized MG. The first self-injectable subcutaneous complement inhibitor, taken as a daily injection at home. Supported by the RAISE trial. By UCB.

Meningococcal vaccination is mandatory. All complement inhibitors increase the risk of meningococcal infection — a rare but serious bacterial infection. You must receive meningococcal vaccines (both MenACWY and MenB) at least 2 weeks before starting any complement inhibitor. If treatment is urgent, you can start with antibiotic prophylaxis while the vaccines take effect. Vaccination lowers but does NOT eliminate the risk. Life-threatening meningococcal infections can occur even after vaccination. Carry information about your complement inhibitor treatment at all times. Learn the signs of meningococcal infection: sudden high fever, severe headache, stiff neck, and a dark purple/red rash — seek emergency care immediately if these occur.

All three complement inhibitors block the C5 component of the complement cascade, but they differ significantly in convenience:

Eculizumab (Soliris): The original complement inhibitor (approved 2017). Requires IV infusion at a clinic every 2 weeks. Now also approved for pediatric patients aged 6+ (February 28, 2025). The most experience and longest track record.
Ravulizumab (Ultomiris): A longer-acting version of eculizumab. IV infusion every 8 weeks after loading doses — significantly more convenient, requiring only 6–7 clinic visits per year instead of 26. Supported by the CHAMPION-MG trial.
Zilucoplan (Zilbrysq): A small-molecule complement inhibitor given as a daily subcutaneous self-injection at home. No clinic visits needed for dosing. The only SC complement inhibitor. Some people prefer the independence of home self-injection; others prefer the less frequent clinic visits of ravulizumab.

All three are approved only for AChR-positive generalized MG (complement inhibitors are less effective in MuSK-MG because MuSK antibodies do not efficiently activate complement). Your neurologist will help choose based on your preference for home injection versus clinic infusion, dosing frequency preference, and insurance coverage.

B-cell targeted therapies — going after the source

B cells are the immune cells that mature into the antibody-producing cells driving MG. Targeting B cells can reduce or eliminate the production of harmful antibodies:

Inebilizumab (UPLIZNA) — FDA-approved December 12, 2025 for adults with AChR-positive and MuSK-positive generalized MG. This is the first and only CD19-targeted B-cell therapy approved for MG. It depletes a broader range of B cells than rituximab (which targets CD20). Supported by the MINT Phase 3 trial — the largest biologic trial in MG to include both AChR+ and MuSK+ patients (238 adults). In the MINT trial, inebilizumab demonstrated statistically significant improvement in MG-ADL and QMG scores vs. placebo. Steroid reduction was achieved in both arms (87.4% inebilizumab vs. 84.6% placebo reached ≤5 mg/day), but the primary benefit was in disease activity control (MG-ADL, QMG outcomes) rather than steroid reduction alone. Dosing is exceptionally convenient: two startup infusions 2 weeks apart, then once every 6 months. By Amgen.
Rituximab (Rituxan) — an anti-CD20 B-cell depleting antibody. Not FDA-approved for MG but widely used off-label, especially in MuSK-MG where it produces sustained remission rates of 60–80%. The RINOMAX trial (2022) showed significant benefit in new-onset generalized MG, with long-term follow-up data (2025) demonstrating benefit up to 12 months. Typically given as induction doses followed by retreatment every 6 months or guided by B-cell counts.

Thymectomy — surgery that can change the course of MG

The thymus gland, located behind the breastbone, plays a role in MG by harboring immune cells that produce harmful antibodies. Removing it (thymectomy) has two distinct indications:

Thymoma-associated MG — if a thymoma is found, surgical removal is mandatory. Thymomas are usually not aggressive, but they must be removed and monitored.
Non-thymomatous AChR-positive generalized MG — the landmark MGTX trial (published in the New England Journal of Medicine, 2016) proved that thymectomy benefits patients aged 18–65 with AChR-positive generalized MG even when there is no thymoma. Patients who had thymectomy needed less prednisone and had better MG control over 3+ years.

Thymectomy is typically done through minimally invasive surgery (robotic-assisted or video-assisted thoracoscopic surgery, VATS) when possible, though open sternotomy may be needed for thymomas with invasion. Benefits may take months to years to fully manifest. Your team will optimize your MG with IVIG or PLEX before surgery to minimize perioperative weakness.

Before surgery:

Your MG will be optimized with medication adjustments, and often IVIG or PLEX, to ensure you are as strong as possible before the procedure.
Pulmonary function tests may be checked.
You will meet your thoracic surgeon to discuss the approach (minimally invasive vs. open) and expectations.

During surgery:

Minimally invasive thymectomy typically takes 1–3 hours and involves small incisions. Robotic-assisted surgery allows precise removal through tiny access points.
Open sternotomy (splitting the breastbone) is reserved for larger thymomas or those invading nearby structures.
The entire thymus gland is removed, along with surrounding fatty tissue.

After surgery:

Hospital stay is typically 1–3 days for minimally invasive, potentially longer for open surgery.
Recovery at home takes several weeks. Lifting restrictions and activity limitations apply during healing.
Your MG medications will continue after surgery and are adjusted gradually over months to years based on your response.
Benefits of thymectomy may not be immediately apparent — improvement often develops gradually over 6–24 months, and some patients see continued improvement for years.
If a thymoma was removed, follow-up imaging will be scheduled to monitor for recurrence.

Recommended: Thymoma-associated MG (any age); non-thymomatous AChR-positive generalized MG in adults aged 18–65 (MGTX trial evidence).
Uncertain benefit: Patients over 65 (limited trial data, though some centers operate on selected older patients); ocular-only MG; seronegative MG.
Not recommended: MuSK-positive MG (the thymus does not play the same pathologic role).

After thymectomy, expect a hospital stay of 1–3 days for minimally invasive surgery, with several weeks of recovery at home. Immunosuppressive medications are typically continued and adjusted over time based on your response.

The MG treatment pipeline is exceptionally active. While these are not yet approved, they represent the next wave of innovation:

Descartes-08 (mRNA-based CAR-T therapy) — a groundbreaking approach using mRNA-engineered T cells that target BCMA-expressing B cells. Unlike traditional CAR-T, it does not require chemotherapy pre-treatment and can be given outpatient. The Phase 3 AURORA trial enrolled its first participant in May 2025, with results expected in late 2026. Featured in Nature Medicine as one of eleven trials predicted to shape medicine in 2026.
IMVT-1402 — a next-generation FcRn inhibitor by Immunovant that binds FcRn differently and avoids reducing albumin levels (a potential safety advantage). Phase 3 trial in MG initiated, with data expected in 2027.
Pozelimab + cemdisiran — a combination of a complement C5 antibody plus an RNA interference agent, aiming for more convenient complement blocking. Phase 3 NIMBLE trial ongoing.
Rese-cel (CD19 CAR-T) — by Cabaletta Bio, recruiting for multiple autoimmune diseases including MG (RESET trials). Positive early data presented at medical conferences in 2025.
Satralizumab — an IL-6 receptor inhibitor being investigated for MG, targeting a key inflammatory pathway.

Clinical trials are not a last resort — they offer access to cutting-edge approaches. Ask your neurologist about trial eligibility at every visit.

With so many options now available, your neurologist considers several factors when building your treatment plan:

Antibody type — AChR+ patients have access to all eight approved drug products (and Vyvgart's May 2026 all-serotype expansion now covers all subtypes). MuSK+ patients benefit most from rituximab, rozanolixizumab, nipocalimab, or inebilizumab. Seronegative patients are often treated similarly to AChR+ patients.
Severity (MGFA Class) — mild disease may need only pyridostigmine and low-dose immunosuppression. Moderate-to-severe disease benefits from earlier use of targeted biologics.
Steroid dependence — if you cannot reduce prednisone below a meaningful threshold, escalation to an FcRn inhibitor, complement inhibitor, or B-cell therapy is warranted.
Thymoma status — thymectomy is part of the plan if a thymoma is present.
Route and schedule preference — some therapies are IV (clinic visits), others are SC self-injections at home, and dosing ranges from daily (zilucoplan) to every 6 months (inebilizumab).
Reproductive planning — some medications are unsafe in pregnancy (mycophenolate, methotrexate); others are being studied or may be continued.
Cost and insurance — targeted biologics are expensive ($300,000–$700,000+/year). Insurance prior authorization is required, and patient assistance programs exist.

Am I a candidate for an FcRn inhibitor, complement inhibitor, or B-cell therapy? Which one and why?
What is the difference between efgartigimod, rozanolixizumab, and nipocalimab for my situation?
If a complement inhibitor is recommended, have I received the required meningococcal vaccines?
Is inebilizumab (UPLIZNA) appropriate for me, and how does it compare to rituximab?
Am I a candidate for thymectomy? What surgical approach would be used?
What should I expect in terms of how quickly the treatment will work?
How will we measure whether the treatment is helping?
What is the plan if this treatment does not work well enough?
Are there any clinical trials I should consider?
What support exists for the cost of these medications?

International Regulatory Approvals for MG Therapies

Access to targeted MG treatments varies significantly by country. This table summarizes the regulatory approval status of MG-specific therapies. "Off-label" means the drug is available but not specifically approved for MG in that jurisdiction.

Drug (Brand)	US FDA	EU EMA	UK MHRA	Japan PMDA	Canada HC	Australia TGA
Eculizumab (Soliris)	Oct 2017 gMG, AChR+; Feb 28, 2025 peds 6+	Aug 2017 refractory gMG	2017 via EU authorization	Dec 2017 gMG	2017 gMG, AChR+	2022 gMG, AChR+
Ravulizumab (Ultomiris)	Apr 2022 gMG, AChR+	Nov 2022 gMG, AChR+	Sep 2022 gMG, AChR+	Sep 2022 gMG	2023 gMG, AChR+	2023 gMG, AChR+
Efgartigimod (Vyvgart)	Dec 2021 (IV) Jun 2023 (SC) May 8, 2026 (all serotypes) gMG; now all adult gMG	Aug 10, 2022 gMG, AChR+	2023 gMG, AChR+	Jan 2022 (IV) Jan 18, 2024 (SC/Vyvdura) gMG, AChR+	2023 gMG, AChR+	Feb 24, 2025 (IV) Feb 20, 2026 (SC) gMG, AChR+
Rozanolixizumab (Rystiggo)	Jun 2023 gMG, AChR+ or MuSK+	2024 gMG, AChR+ or MuSK+	Mar 7, 2024 gMG, AChR+ or MuSK+	2024 gMG	Mar 28, 2025 gMG, AChR+ or MuSK+	Feb 7, 2025 gMG, AChR+ or MuSK+
Zilucoplan (Zilbrysq)	Oct 2023 gMG, AChR+	2024 gMG, AChR+	2024 gMG, AChR+	2024 gMG	Jul 11, 2024 gMG, AChR+	Aug 20, 2024 gMG, AChR+
Nipocalimab (IMAAVY)	Apr 29, 2025 gMG, AChR+ & MuSK+, 12+	Nov 28, 2025 gMG, AChR+ & MuSK+	Under review	Sep 19, 2025 gMG, AChR+ & MuSK+	Dec 5, 2025 gMG, AChR+ & MuSK+	Under review
Inebilizumab (UPLIZNA)	Dec 2025 gMG, AChR+ & MuSK+	Feb 12, 2026 gMG, AChR+ & MuSK+	Under review	Under review	Under review	Under review
Pyridostigmine (Mestinon)	Decades generic	Yes widely available	Yes widely available	Yes widely available	Yes widely available	Yes widely available
Tacrolimus (Prograf)	Off-label not FDA-approved for MG	Off-label	Off-label	Approved for MG standard care in Japan	Off-label	Off-label
Rituximab (Rituxan)	Off-label widely used, not approved for MG	Off-label	Off-label	Off-label	Off-label	Off-label

Critical international difference: tacrolimus. Tacrolimus is standard of care for MG in Japan — approved by PMDA specifically for steroid-refractory or steroid-intolerant MG. It is a cornerstone of the Japanese MG treatment strategy, which emphasizes early, fast-acting immunosuppression. In the US, EU, UK, Canada, and Australia, tacrolimus is off-label for MG and used less frequently. If you are treated in Japan or by a Japanese-trained neurologist, tacrolimus may be offered as a first-line steroid-sparing agent. Dates marked "(verify)" reflect the most recent publicly available information and should be confirmed with national regulatory agencies or your treating neurologist. Regulatory status can change — this table was last updated in June 2026.

Off-label use disclaimer. Several drugs widely used in MG (rituximab, tacrolimus, mycophenolate, cyclosporine, methotrexate, azathioprine) are not FDA-approved specifically for MG but are used off-label based on substantial clinical evidence and guideline recommendations. Off-label use is a standard and accepted practice in medicine. Your neurologist may recommend these based on their clinical judgment and published evidence. Insurance coverage for off-label use varies.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is as important as knowing what does. These therapies were tested in rigorous trials or were once standard care but are no longer recommended for MG. Understanding these helps avoid repeating unsuccessful approaches and shows how the field has progressed.

Etanercept (Enbrel) — TNF-alpha inhibitor — Tested in a pilot study for MG but showed no benefit and some patients worsened. TNF-alpha inhibition is not effective in antibody-mediated diseases like MG and can paradoxically trigger autoimmunity. TNF inhibitors are not used for MG. FAILED
Batoclimab — FcRn inhibitor — Completed a positive Phase 3 trial for MG (58% vs 31% responder rate), but the manufacturer (Immunovant) announced it will not seek FDA approval because batoclimab also reduced albumin levels — a safety concern. Immunovant is instead developing the next-generation IMVT-1402, which avoids this albumin-lowering effect. WITHDRAWN
Edrophonium (Tensilon) test — diagnostic tool — Intravenous edrophonium was historically the classic bedside test for MG. It provided rapid, temporary improvement in weakness. It is now rarely used because of cardiac risks (bradycardia, asystole), the need for IV access, atropine standby, and the availability of safer, more accurate tests (antibody panels, RNS, SFEMG, ice pack test). Edrophonium was discontinued by its manufacturer. DE-ADOPTED
High-dose cyclophosphamide “immune reset” — High-dose intravenous cyclophosphamide was studied as a way to “reset” the immune system in severe, treatment-refractory MG. While some patients improved, the severe toxicity (prolonged immunosuppression, infection risk, infertility, malignancy risk) and the availability of safer targeted biologics have made this approach largely obsolete. It is no longer recommended except in rare, exceptional circumstances. DE-ADOPTED
Thymus irradiation — Before the MGTX trial established the role of surgical thymectomy, some centers used radiation therapy to shrink the thymus as an alternative to surgery. Radiation carries long-term risks (including secondary malignancy) and has been replaced by minimally invasive surgical thymectomy. It is no longer recommended for MG. DE-ADOPTED
Thymectomy for MuSK-positive MG — Early in MG treatment history, thymectomy was performed for all MG subtypes. It is now well established that thymectomy does not benefit MuSK-positive MG, as MuSK-MG pathogenesis is thymus-independent. Thymectomy is no longer recommended for this subtype. DE-ADOPTED

Clinical Trials — Active MG Programs

The MG clinical trial landscape is among the most active in neurology. Trials are not a last resort — they are a recommended treatment option at every disease stage, offering access to therapies not yet available. Below are major active or recently completed trials with verified NCT numbers.

Trial Name	Drug / Approach	Phase	NCT Number	Status
AURORA	Descartes-08 (mRNA CAR-T)	Phase 3	NCT06799247	Recruiting
NIMBLE	Pozelimab + cemdisiran (complement C5)	Phase 3	NCT05070858	Active
IMVT-1402 MG	IMVT-1402 (next-gen FcRn inhibitor)	Phase 3	NCT07039916	Recruiting
VIVACITY-MG3	Nipocalimab (IMAAVY)	Phase 3	NCT04951622	Completed → Approved
MINT	Inebilizumab (UPLIZNA)	Phase 3	NCT04524273	Completed → Approved
ADAPT / ADAPT+	Efgartigimod (Vyvgart)	Phase 3	NCT03669588	Completed → Approved
CHAMPION-MG	Ravulizumab (Ultomiris)	Phase 3	NCT03920293	Completed → Approved
MycarinG	Rozanolixizumab (Rystiggo)	Phase 3	NCT03971422	Completed → Approved
RAISE	Zilucoplan (Zilbrysq)	Phase 3	NCT04115293	Completed → Approved
RINOMAX	Rituximab (new-onset gMG)	Phase 2/3	NCT02950155	Completed
ADAPT SERON	Efgartigimod (Vyvgart) — seronegative gMG	Phase 3	NCT06298552	Completed → Led to all-serotype expansion
ADAPT-NXT	Efgartigimod SC (Vyvgart Hytrulo) — long-term safety	Phase 3	NCT04980495	Active
REFINE	Rituximab vs. conventional immunosuppressants in gMG	Phase 3	NCT05868837	Recruiting
PROBE	Rituximab as initial therapy in MuSK-MG	Phase 3	NCT06342544	Recruiting
MG0020	Next-generation targeted agent (Phase 2/3)	Phase 2/3	NCT05681715	Active
UPSTREAM-MG	Telitacicept (BLyS/APRIL dual inhibitor, RemeGen)	Phase 3	NCT06456580	Recruiting
RELIEVE	Batoclimab (FcRn inhibitor)	Phase 3	NCT05403541	Positive results; manufacturer not seeking FDA approval (see Failed Therapies)
KYSA-6 MG trials	KYSA-6 (next-gen complement inhibitor)	Phase 2/3	Search “KYSA-6” at ClinicalTrials.gov	Active

How to find MG clinical trials:

ClinicalTrials.gov — search "myasthenia gravis" and filter by recruiting status, location, and phase.
MGFA trial registry — myasthenia.org maintains a patient-friendly list of ongoing MG trials.
Your neurologist — ask about trial eligibility at every visit. Your antibody type, severity, and prior treatment history determine which trials you may qualify for.
In Utah: the University of Utah Neurosciences Center is the primary center for MG clinical trial access. Contact: (801) 585-7575.

Clinical trials are not a last resort. Many trials are designed for patients who are doing reasonably well but want access to potentially better therapies. Participation in a trial means closer monitoring, expert care, and contributing to knowledge that will help future MG patients. All trials provide standard-of-care treatment as a baseline — you are not denied effective therapy by participating.

Living Well & Crisis Prevention

Managing MG well goes far beyond medication. Preventing myasthenic crisis, avoiding dangerous drug interactions, conserving energy wisely, and caring for your emotional health are all critical to living a full life with MG.

⚡ Myasthenic crisis is a medical emergency. If you experience rapidly worsening difficulty breathing, swallowing, or speaking — especially if you feel like you cannot take a deep breath — call emergency services immediately. Crisis means your breathing muscles are failing and you may need mechanical ventilation. It is treatable in an ICU with rapid IVIG or plasma exchange, but delay can be fatal. Know the warning signs. Have a plan.

Recognizing crisis warning signs

Myasthenic crisis does not always happen suddenly. Often there are warning signs in the hours or days beforehand:

Increasing shortness of breath, especially when lying flat
Difficulty completing sentences without pausing to breathe
Worsening difficulty swallowing or managing saliva
Voice becoming markedly weaker or more nasal
New inability to hold up your head
Feeling that your breathing is shallow or your cough is weak

If you notice these worsening, contact your neurology team before it becomes an emergency. Early hospital admission for monitoring and treatment is far better than emergency intubation.

What triggers a crisis

Infection — the most common trigger by far. Even a routine upper respiratory infection, urinary tract infection, or pneumonia can tip MG into crisis. This is why reporting fevers and infections to your neurology team early is so important — early treatment of the infection can prevent crisis.
Medication changes — stopping or rapidly changing MG medications, or starting a medication that worsens MG (see list below). Never abruptly stop your MG medications without medical guidance.
Surgery and anesthesia — always inform your surgical and anesthesia team of your MG. Pre-operative optimization with IVIG or PLEX may be needed.
Physical or emotional stress — overexertion, extreme heat, and major emotional stress can worsen symptoms.
Pregnancy and postpartum — MG can worsen, especially in the first trimester and postpartum period.
Tapering steroids too quickly — rapid prednisone reduction can provoke a flare. Steroid tapers should be gradual and supervised.

If you or a loved one is admitted for myasthenic crisis, here is what to expect:

ICU admission: crisis is managed in an intensive care unit where breathing can be closely monitored.
Breathing monitoring: your forced vital capacity (FVC — how deeply you can breathe) and negative inspiratory force (NIF) will be measured regularly. If FVC drops below a critical threshold, mechanical ventilation (a breathing machine) may be needed temporarily.
Rapid treatment: IVIG or plasma exchange (PLEX) will be started promptly. Both are equally effective; PLEX tends to work slightly faster (days) while IVIG takes about a week. The choice depends on availability and your specific situation.
Identifying the trigger: the team will look for what triggered the crisis — usually an infection — and treat it.
Recovery: most people recover from myasthenic crisis and return to their previous level of function. Crisis is scary but treatable. The key is getting to the hospital quickly.
After crisis: your maintenance MG therapy will be reassessed and likely escalated to prevent future episodes.

Medications that can worsen MG — your safety list

Every MG patient must know this list. Carry a medication alert card and inform all healthcare providers:

Antibiotics: aminoglycosides (gentamicin, tobramycin), fluoroquinolones (ciprofloxacin, levofloxacin), high-dose macrolides (azithromycin, erythromycin), telithromycin (Ketek) — CONTRAINDICATED in MG (can cause fatal exacerbation), clindamycin, polymyxins (colistin)
Heart/blood pressure drugs: beta-blockers (propranolol, atenolol, metoprolol), some calcium channel blockers, procainamide, quinidine
Magnesium sulfate (used IV in hospitals for various conditions)
Iodinated contrast agents (used in CT scans and angiography — can transiently worsen MG; inform radiology of your diagnosis)
Anti-malarial/anti-rheumatic drugs: chloroquine and hydroxychloroquine (can exacerbate MG weakness)
Anti-seizure drugs: phenytoin (can worsen neuromuscular transmission)
Lithium (used for bipolar disorder — can worsen MG symptoms)
D-penicillamine (used for rheumatoid arthritis and Wilson disease)
Immune checkpoint inhibitors (cancer immunotherapy drugs including ipilimumab, nivolumab, pembrolizumab — can cause de novo MG or severely exacerbate existing MG; this is an increasingly recognized and potentially life-threatening complication)
Botulinum toxin (Botox) — even cosmetic injections
Neuromuscular blocking agents (used in anesthesia — depolarizing agents like succinylcholine must be avoided; non-depolarizing agents used with extreme caution)
Statins (rare, but some patients report worsening)

This list is not exhaustive. Whenever any doctor, dentist, or pharmacist prescribes a new medication, ask: "Is this safe for someone with myasthenia gravis?" Do not assume they will check automatically. Many emergency departments and urgent care centers are not familiar with MG drug interactions. Your medication alert card is your best defense.

Carry an MG alert. A medical alert bracelet or card listing your MG diagnosis, your medications, and drugs to avoid can be life-saving in an emergency when you may not be able to speak. The MGFA provides downloadable wallet cards at myasthenia.org. Keep one in your wallet, one in your car, and give one to your caregiver. Consider a medical alert bracelet or necklace for situations where a card may not be found.

MG fatigue is real, and it is different from ordinary tiredness. Your muscles literally weaken with use and recover with rest. Learning to pace yourself is one of the most important practical skills:

Plan your most demanding activities for your best time of day — many people with MG are strongest in the morning, with weakness building through the day.
Build rest periods into your schedule — brief rests (even 10–15 minutes with eyes closed) can partially restore strength.
Time pyridostigmine doses strategically — take doses 30–60 minutes before meals or activities that require strength.
Manage heat exposure — heat can worsen MG symptoms. Stay cool in hot weather, use cooling vests if needed, and avoid hot baths or saunas.
Eating and swallowing — if chewing and swallowing are affected, eat softer foods, take smaller bites, sit upright, and eat when pyridostigmine is working (about 30 minutes after a dose). Avoid talking while eating.
Exercise is important but must be adapted — moderate, consistent activity is beneficial. Avoid exhausting workouts. Swimming should be supervised. Discuss an exercise plan with your team.

MG is often called an "invisible illness" — you may look perfectly healthy while struggling with profound fatigue, double vision, or difficulty swallowing. The unpredictability of symptoms (good days and bad days), the frustration of being doubted, and the chronic nature of the disease take a real emotional toll. Depression and anxiety are common and completely understandable.

These feelings are also treatable. Ask your neurology team about counseling, support groups, and when appropriate, medication for depression or anxiety. Connecting with others who have MG — through the MGFA, online communities, or local support groups — helps many people feel less alone. Seeking support is a sign of strength.

If you are struggling with the emotional impact, tell your doctor. Mental health is part of MG care.

MG does not prevent pregnancy, but it requires careful planning with your neurology and obstetric teams:

Medications to stop before pregnancy: mycophenolate mofetil and methotrexate are teratogenic and must be stopped well in advance. A switch to a pregnancy-safe alternative is needed.
Generally safe during pregnancy: pyridostigmine, azathioprine, cyclosporine, IVIG, and PLEX.
Complement inhibitors and FcRn inhibitors: discuss with your team. Nipocalimab is being studied specifically for maternal-fetal conditions where harmful antibodies cross the placenta.
Neonatal transient MG: about 10–20% of newborns of MG mothers have temporary weakness from maternal antibodies crossing the placenta. This resolves on its own within weeks. Neonatal teams are prepared for this.
MG itself may improve, worsen, or stay the same during pregnancy — each pregnancy is different.

Many people with MG continue to work and lead active professional lives, especially with modern treatment. If your MG affects your ability to work:

The Americans with Disabilities Act (ADA) may entitle you to workplace accommodations such as flexible scheduling, rest breaks, modified duties, or temperature-controlled environments.
If MG prevents you from working, Social Security Disability (SSDI) is available. MG is a recognized qualifying condition, though the application process can be slow. Documentation from your neurologist is essential.
Talk to your neurology team's social worker or the MGFA for guidance on navigating disability and accommodation processes.

MG can occur in children and teenagers. Juvenile MG has some important differences from adult MG:

Ocular MG is more common in children, particularly in East Asian populations. Some children with purely ocular MG may experience spontaneous remission.
Treatment generally follows adult principles, with attention to growth, development, and school participation.
As of February 28, 2025, eculizumab (Soliris) became the first treatment approved for pediatric gMG (ages 6 and older with AChR+ generalized MG). Meningococcal vaccination is required.
As of April 29, 2025, nipocalimab (IMAAVY) is approved for patients aged 12 and older — the first FcRn inhibitor available for adolescents.
Pyridostigmine, corticosteroids, and conventional immunosuppressants are used similarly to adults.
A pediatric neurologist with neuromuscular expertise should be involved in care.

Any surgery or dental procedure requires special planning if you have MG:

Always inform your surgeon and anesthesiologist about your MG before any procedure, no matter how minor. Provide your medication list and alert card.
Certain anesthesia agents are dangerous: MG patients are exquisitely sensitive to non-depolarizing neuromuscular blocking agents (rocuronium, vecuronium). The initial dose should be reduced by 70–80% compared to standard dosing, with careful neuromuscular monitoring (train-of-four). Succinylcholine (a depolarizing neuromuscular blocker) should be avoided if possible due to unpredictable recovery in MG patients — pyridostigmine inhibits the plasma cholinesterase that metabolizes succinylcholine, risking prolonged paralysis. All MG patients must inform their surgeons and anesthesiologists of their diagnosis before any procedure, no matter how minor.
Pre-operative optimization: your neurologist may recommend IVIG or plasma exchange before surgery to ensure your MG is as well-controlled as possible, reducing the risk of post-operative respiratory complications.
Post-operative monitoring: plan for an ICU stay or close monitoring after major surgery, as the stress of surgery can trigger a myasthenic exacerbation. Breathing function (forced vital capacity) should be monitored closely.
Pain management: some pain medications can worsen MG. Your team will choose appropriate post-operative pain control.
Dental work: local anesthetics are generally safe. Inform your dentist about your MG and your medication list. Avoid prolonged procedures that require you to hold your mouth open for extended periods — schedule rest breaks.

Staying current with vaccines is important because infection is the most common trigger of myasthenic crisis. However, certain considerations apply:

Inactivated vaccines (flu shot, COVID, pneumococcal, shingles/Shingrix, tetanus) are generally safe and recommended.
Live vaccines (MMR, varicella, live-attenuated influenza nasal spray) should generally be avoided if you are on immunosuppressive therapy. Discuss with your team.
Meningococcal vaccines (MenACWY + MenB) are mandatory if you are starting a complement inhibitor. Ideally given at least 2 weeks before treatment begins. Booster schedule: MenACWY must be boosted every 5 years for the duration of complement inhibitor therapy. MenB boosters follow the product-specific protocol (Bexsero or Trumenba) if complement inhibition continues. Your neurology team should track booster dates.
COVID vaccination is recommended. MG itself and immunosuppressive treatment increase the risk of severe COVID. Be aware that any vaccine can temporarily worsen MG symptoms — this is usually mild and short-lived, and the benefit of vaccination outweighs the risk.
Timing: if possible, schedule vaccinations when your MG is stable, not during a flare.

While most people with MG do well with modern treatment, it is wise to have conversations about your wishes regarding emergency medical care, especially given the possibility of myasthenic crisis:

Complete an advance directive (living will) and designate a healthcare proxy (someone who can make medical decisions if you cannot).
Make sure your documents state that myasthenic crisis is a treatable emergency — mechanical ventilation for MG crisis is a temporary, life-saving measure, not a sign of end-stage disease. Most people recover from crisis and return to their previous level of function.
Share your advance directive with your neurologist, your primary care doctor, and your designated proxy.
Review and update these documents periodically, especially if your MG status changes significantly.

👪 For Caregivers. The section below is written specifically for partners, family members, and friends supporting someone with myasthenia gravis.

Caregiver Notes

Caring for someone with MG requires understanding a disease that is invisible, unpredictable, and chronic. Your role is essential — especially in recognizing worsening, managing medications, and providing practical and emotional support.

Medication timing is critical. MG medications — especially pyridostigmine — work on a schedule. Help maintain a consistent medication routine, and know when doses are due. Keep a written or app-based medication schedule.
Learn the early signs of worsening. Watch for increasing drooping of eyelids, more nasal or weak voice, coughing during meals (difficulty swallowing), and increased fatigue. These can signal a flare or approaching crisis.
Understand that "looking fine" does not mean feeling fine. MG weakness and fatigue are real even when the person appears healthy. Avoid dismissing symptoms or pushing the patient to "push through."
Help manage energy. Support pacing — plan activities during the patient's strongest hours, allow rest periods, and help with physically demanding tasks.
Attend infusion appointments. FcRn inhibitor and complement inhibitor infusions may take 1–2 hours. Be available for transportation and companionship.
Keep the medication alert card accessible. Know where it is and what is on it, in case of emergency.
Insurance and prior authorizations. Targeted biologic therapies often require extensive paperwork. Help navigate prior authorizations, appeals, and patient assistance programs.

Call 911 or go to the emergency room immediately if:

The person is struggling to breathe or cannot take a deep breath
They cannot swallow their own saliva or are drooling
They cannot hold their head up
Speech has become so weak it is unintelligible

Contact the neurology care team promptly for:

Fever or signs of infection (the most common crisis trigger)
Noticeable worsening of swallowing, speech, or eye symptoms over hours or days
New or worsening limb weakness beyond the usual pattern
A new medication was prescribed by another doctor (check whether it is safe with MG)
Missing multiple doses of MG medication

Know your neurology team's after-hours contact number. Post it where you can find it immediately.

Caring for someone with a chronic, unpredictable condition is exhausting. The constant vigilance for worsening, the fluctuating capabilities, and the emotional weight are real. Protect yourself:

Keep your own medical appointments and sleep schedule.
Accept concrete offers of help (meals, rides, errands).
Consider a caregiver support group — the MGFA and other organizations run them.
Know that your wellbeing is part of the patient's support system, not separate from it.
If you are feeling burned out, talk to someone. Caregiver burnout is common and treatable.

Keep a current medication list (with doses and schedule) in an accessible location and on your phone.
Ensure the patient wears or carries a medical alert bracelet/card at all times.
Know the location of the nearest emergency room and the after-hours number for the neurology team.
If the patient takes a complement inhibitor, know the signs of meningococcal infection (sudden high fever, stiff neck, headache, rash) and seek emergency care immediately.
Keep a "crisis go-bag" packed: current medication list, insurance cards, the MG alert card, a phone charger, and comfort items for a potential hospital stay.

What are the specific warning signs I should watch for that mean MG is worsening toward crisis?
What is the after-hours and emergency contact number for the neurology team?
Which of my other medications are safe with MG, and which should be avoided or changed?
If I need surgery or a dental procedure, what precautions are needed?
What is the plan for managing my MG during an infection?
How should I manage MG symptoms in extreme heat?
What exercise is safe, and what should I avoid?
If I am on a complement inhibitor, what are the signs of meningococcal infection?
Are there counseling, support groups, or social work resources for me and my caregiver?
Should I wear a medical alert bracelet? Where can I get an MG alert card?

Pregnancy & Neonatal MG

MG does not prevent pregnancy, but it requires coordinated planning between your neurologist and obstetrician, ideally starting before conception. MG behavior during pregnancy is unpredictable — about one-third of patients improve, one-third worsen, and one-third stay the same. Worsening is most common in the first trimester and postpartum period.

Medication safety in pregnancy

Must stop before conception: Mycophenolate mofetil (CellCept) carries an FDA Boxed Warning for first-trimester pregnancy loss and congenital malformations (facial clefts, microtia). Must be discontinued at least 6 weeks before conception. Requires dual contraception and enrollment in the Mycophenolate REMS program while on therapy. Methotrexate is also teratogenic and must be discontinued at least 3 months before conception. Switch to a pregnancy-safe alternative first.
Generally considered safe: pyridostigmine (Mestinon), azathioprine, cyclosporine, IVIG, and plasma exchange (PLEX).
Complement inhibitors: limited pregnancy data. Eculizumab has been used in PNH (paroxysmal nocturnal hemoglobinuria) during pregnancy with favorable outcomes, but MG-specific pregnancy data are limited. Discuss risk/benefit with your team.
FcRn inhibitors: nipocalimab is being studied specifically for maternal-fetal conditions where harmful antibodies cross the placenta. Other FcRn inhibitors have limited pregnancy data. Important: FcRn blockers (Vyvgart, Rystiggo, IMAAVY) reduce maternal-fetal IgG transport across the placenta. This could leave the neonate transiently hypogammaglobulinemic (with low antibody levels) and at increased infection risk at birth. The mechanism of lowering IgG could affect the baby's passive immunity transfer, particularly in the third trimester. Discuss timing of treatment cycles relative to delivery with your neurology and obstetric teams.
Rituximab: generally avoided in the third trimester due to risk of neonatal B-cell depletion. If used, timing relative to conception is important.

Transient neonatal myasthenia gravis

About 10–20% of newborns born to mothers with MG develop temporary MG symptoms caused by maternal antibodies crossing the placenta. This is called transient neonatal MG. It typically manifests within hours to days of birth with the following signs:

Weak or feeble cry
Poor suckling and feeding difficulty — may require nasogastric (NG) tube feeding temporarily
Hypotonia (generalized "floppiness")
Variable respiratory distress — may range from mild to requiring respiratory support

Key points:

It is self-limiting — symptoms resolve as maternal antibodies degrade, typically within 2–4 weeks.
The neonatal team should be informed of the mother's MG diagnosis before delivery so they can monitor the baby appropriately.
Management is primarily supportive: feeding support (temporary NG tubes if needed), respiratory monitoring, and skin-to-skin contact. In severe cases, low-dose pyridostigmine or infant IVIG may be used.
Severity does not correlate reliably with the mother's disease severity — a mother with well-controlled MG can still have an affected newborn.
Transient neonatal MG is not the same as juvenile MG or congenital myasthenic syndromes. It is temporary and does not mean the child will develop MG later in life.

Delivery planning

Vaginal delivery is generally preferred when MG is stable; cesarean section is reserved for obstetric indications, not MG itself.
Anesthesia considerations: regional anesthesia (epidural, spinal) is preferred over general anesthesia when possible. The anesthesia team must be aware of MG and avoid problematic medications (succinylcholine, aminoglycoside antibiotics).
Magnesium sulfate, commonly used for preeclampsia, can severely worsen MG. Alternative anticonvulsants should be used.
Breastfeeding is generally compatible with pyridostigmine and azathioprine. Discuss other medications with your team.

Plan ahead. If you are considering pregnancy, talk to your neurologist before conception to optimize your MG treatment and switch off unsafe medications. A stable MG state before pregnancy gives the best chance of a smooth pregnancy and delivery.

Uncertainties & Evidence Gaps

MG treatment has advanced dramatically, but important questions remain unanswered. Honest acknowledgement of these gaps helps patients make informed decisions and highlights where research is needed most.

Optimal sequencing of biologics: with eight targeted drug products now approved (plus Vyvgart's all-serotype expansion), there is no high-quality evidence on the optimal order in which to use them. Should FcRn inhibitors come before complement inhibitors? Should B-cell therapy be tried before FcRn inhibitors? Head-to-head comparative trials are needed but rare due to cost and complexity. Current treatment sequencing is largely guided by expert opinion and practical factors (antibody subtype, route preference, insurance).
Long-term safety of newer biologics: efgartigimod, rozanolixizumab, nipocalimab, zilucoplan, and inebilizumab have only been approved for 1–4 years. Long-term safety data (5+ years) are not yet available. Registries and post-marketing surveillance are ongoing.
Biomarkers for treatment response: there is no reliable blood test or biomarker that predicts which targeted therapy will work best for an individual patient. Treatment selection remains largely empirical.
Seronegative MG treatment: patients who test negative for AChR, MuSK, and LRP4 antibodies (~5–10%) have the least evidence guiding their treatment. Most clinicians treat them similarly to AChR+ patients, but there are no biologic trials specifically enrolling seronegative patients.
Thymectomy in older adults: the landmark MGTX trial enrolled patients aged 18–65. The benefit of thymectomy in patients over 65 is uncertain, and this remains an active area of clinical debate.
Cure vs. long-term remission: current therapies control MG but rarely cure it. Whether any of the newer approaches (CAR-T, B-cell depletion) can achieve durable drug-free remission in a significant proportion of patients remains to be determined.
Pediatric MG: only two therapies are approved for pediatric MG (eculizumab for ages 6+, nipocalimab for ages 12+). Pediatric trial enrollment is slow, and many treatments are used off-label in children.
MG and COVID-19: the interaction between MG, immunosuppressive therapy, and SARS-CoV-2 infection continues to be studied. MG patients on immunosuppressive therapy may have reduced vaccine responses and higher risks from infection.

These uncertainties do not mean that treatment is guesswork — current therapies are effective for most patients. They highlight that MG research is ongoing and that participating in clinical trials can help answer these questions for future patients.

Support & Resources

You do not have to navigate myasthenia gravis alone. Specialized neuromuscular centers, patient organizations, and financial-assistance programs exist specifically to help.

Utah resources

University of Utah Health — Neuromuscular Program, Clinical Neurosciences Center
175 N Medical Dr E, Salt Lake City, UT 84132
Phone: (801) 585-7575
The primary Utah center for MG specialist care with fellowship-trained neuromuscular neurologists, including Dr. Kyle W. Mahoney, MD (Neuromuscular Fellowship trained, autoimmune neuromuscular junction specialist) and Dr. Tammy Smith, MD, PhD (Assistant Professor, Autoimmune Neurology). Comprehensive diagnostic capabilities including repetitive nerve stimulation (RNS), single-fiber EMG (SFEMG), and antibody panels. Home to ARUP Laboratories, a national reference laboratory with consultation hub for cell-based autoantibody assays (clustered AChR, MuSK cell-based assays) — critical for diagnosing seronegative or atypical MG presentations. Infusion center on-site for IVIG, Soliris/Ultomiris, Vyvgart, IMAAVY, UPLIZNA, and all FDA-approved MG biologics. Thymectomy via cardiothoracic surgery (robotic-assisted VATS available). Primary center for MG clinical trial access in Utah — the University of Utah Clinical Neurosciences Center served as an active site for the Phase 3 UPLIZNA MINT trial (NCT04524273) and continues recruiting for next-generation protocols. Search ClinicalTrials.gov for active MG trials at University of Utah.
Intermountain Medical Center — Intermountain Health Neurosciences
5121 S Cottonwood St, Murray, UT 84107
Phone: (801) 507-7000
Neurosciences program with infusion center capabilities (IVIG and SubQ Ig). MG diagnosis and management across the Wasatch Front with established referral pathways to the University of Utah for refractory/complex cases, biologic therapy, and thymectomy.
VA George E. Wahlen Medical Center (Salt Lake City VAMC)
500 Foothill Dr, Salt Lake City, UT 84148
Phone: (801) 582-1565 | VISN 19
Neurology service for veterans with MG. Can coordinate referrals to University of Utah for subspecialty care, biologic infusions, and thymectomy. Ask about the Community Care program if local MG expertise is limited.
Utah infusion centers (critical for MG biologics) — many MG drugs (Soliris, Ultomiris, Vyvgart IV, IMAAVY, UPLIZNA) require specialized infusion centers with REMS certification (for complement inhibitors). Key Utah infusion sites include:
- University of Utah Health Outpatient Infusion Suites — the primary academic site for all FDA-approved MG biologics, with REMS-certified complement inhibitor administration and on-site neuromuscular team for monitoring.
- Option Care Health (Salt Lake City / Murray) — a national home and ambulatory infusion provider with locations in the Salt Lake City metro area offering IVIG, biologic infusions, and home infusion services for qualifying patients.
- Advanced Infusion Care — independent infusion center in the Salt Lake City area providing outpatient infusion services for specialty biologics.
SubQ self-injection therapies (Vyvgart Hytrulo, Rystiggo, Zilbrysq) can be administered at home after training. Ask your neurology team which infusion center is best for your specific medication and insurance plan.

Utah support resources

MGFA Intermountain Chapter — check myasthenia.org for local support group meetings in the Salt Lake City / Intermountain West area.
Utah Division of Services for People with Disabilities (DSPD) — (801) 538-4200. State agency providing disability support services, home and community-based services, and employment services for people with chronic conditions including MG.
Utah Vocational Rehabilitation — (801) 887-9500. Job placement, accommodations, and training for people whose disability affects their ability to work.

Nearest specialized MG centers for complex cases

How to choose a center in Utah.

University of Utah Neurosciences Center — best for: academic subspecialty care, clinical trial access, thymectomy referral, biologic infusions (all FDA-approved MG therapies), complex/refractory cases, MuSK-MG, second opinions, and advanced diagnostic testing via ARUP Laboratories (cell-based autoantibody assays for seronegative or atypical presentations). The primary MG referral center in the Intermountain West.
Intermountain Health Neurosciences — best for: community-based MG management, in-network convenience across the Wasatch Front, IVIG/SCIg infusions, and coordination with primary care. Established referral pathways to U of U for escalation.
VA George E. Wahlen Medical Center — best for: veterans with MG. Neurology service on-site; can coordinate Community Care referrals to U of U for subspecialty care, biologics, and thymectomy.

For complex or refractory cases beyond Utah: Mayo Clinic Arizona (Scottsdale, ~650 mi), Barrow Neurological Institute (Phoenix, ~650 mi), and University of Colorado Neuromuscular Medicine (Aurora, ~525 mi) are the nearest major out-of-state referral centers with dedicated MG programs and extensive clinical trial portfolios.

University of Colorado — Neuromuscular Medicine, Aurora, CO (~525 miles). Academic neuromuscular program with MG clinical trial participation.
Mayo Clinic Arizona, Scottsdale, AZ (~650 miles). Major multi-specialty center with neuromuscular medicine, thymectomy capability, and extensive MG clinical trial portfolio.
Barrow Neurological Institute, Phoenix, AZ (~650 miles). Comprehensive neuromuscular program with MG expertise.

National organizations

Myasthenia Gravis Foundation of America (MGFA) — myasthenia.org — the leading MG-specific organization. Provides patient education, MG-specific nurse hotline, downloadable medication alert cards, local support group chapters (including Intermountain West), and advocacy for access to treatments. Sets international standards for MG classification and outcome measures used in clinical trials worldwide.
GBS|CIDP Foundation International — covers MG and related neuromuscular conditions, with patient resources and support networks.
National Organization for Rare Disorders (NORD) — patient assistance programs, educational resources, and advocacy for rare disease patients including those with MG.
Rare Disease Foundation — financial assistance programs for people with rare diseases.

International MG organizations

Myasthenia Gravis Association (UK) — mga-charity.org — the UK's leading MG charity. Patient information, helpline, regional support groups across England, Scotland, Wales, and Northern Ireland.
European Myasthenia Gravis Association (EuMGA) — umbrella organization connecting MG patient associations across Europe.
Myasthenia Gravis Society of Canada — mgcanada.org — patient support, education, and advocacy for Canadians with MG.
Myasthenia Alliance Australia — myasthenia.org.au — patient resources, support groups, and physician directory for Australians with MG.
Japan Myasthenia Gravis Association (JMGA) — patient advocacy and resources in Japan, where MG treatment approaches differ from Western practice (see tacrolimus section above).

Global access disparity. Targeted biologic therapies for MG cost $300,000–$700,000+ per year in the US. In many countries, these drugs are unavailable or unaffordable. Pyridostigmine, prednisone, and azathioprine remain the global backbone of MG treatment at less than $2,000/year. Biosimilar development (particularly for eculizumab and rituximab) could improve global access in the coming years. If you are living in a country where biologics are not available, the MGFA and EuMGA can provide guidance on access programs and compassionate-use options.

☎ Mental health crisis resources. Living with MG can take a significant emotional toll. If you or someone you know is struggling with depression, anxiety, or thoughts of self-harm: 988 Suicide & Crisis Lifeline — call or text 988 (US, 24/7). Crisis Text Line — text HOME to 741741. SAMHSA National Helpline — 1-800-662-4357 (free, confidential, 24/7). Seeking help is a sign of strength, not weakness. Mental health care is part of comprehensive MG management.

International context

MG care varies significantly around the world:

United States and European Union — all major FcRn inhibitors, complement inhibitors, and inebilizumab are approved or under regulatory review. Access depends heavily on insurance and prior authorization.
Japan — tacrolimus (FK506) is approved in Japan specifically for myasthenia gravis (steroid-refractory or steroid-intolerant MG; typically low-dose ~3 mg/day). It is a calcineurin inhibitor and a cornerstone of the Japanese MG treatment paradigm, which emphasizes “early fast-acting treatment” — combining early IVIG or plasma exchange with low-dose steroids and a calcineurin inhibitor to reach minimal-symptom status quickly. Tacrolimus is not FDA-approved for MG; US use is off-label. Eculizumab and efgartigimod are also approved in Japan. The Japanese Neurology Society guidelines emphasize early thymectomy.
United Kingdom — NICE technology appraisals govern access. Eculizumab is available for refractory AChR+ gMG through a managed access agreement. Efgartigimod is under review. The Myasthenia Gravis Association UK provides excellent patient resources.
Australia and Canada — regulatory approvals are progressing. Access through public health systems may have additional eligibility criteria.
Lower-income countries — pyridostigmine, prednisone, and azathioprine remain the backbone of treatment due to cost barriers. Targeted biologics can cost $300,000–$700,000+ per year in the US, while conventional therapy costs less than $2,000/year in many countries. Biosimilar development for eculizumab could improve global access in the coming years.

International approaches differ meaningfully. The Japanese approval of tacrolimus specifically for MG — and Japan’s “early fast-acting treatment” strategy combining rapid immunotherapy with calcineurin inhibitors — contrasts with some Western step-up approaches that escalate treatment more gradually. These differences illustrate that MG treatment strategies vary by country and guideline system. If you are treated outside the US, or are researching options from other countries, discuss the rationale with your neurologist — what is standard care in one country may be off-label or unavailable in another.

The MGFA sets international standards for MG classification and outcome measures, and these are used in clinical trials and practice worldwide regardless of location.

Help with the cost of treatment. Modern MG biologics are among the most expensive drugs in medicine. Financial stress is a real burden that can affect treatment adherence. Ask your neurology team's financial navigator or social worker early — before bills accumulate. Resources include manufacturer patient-assistance programs (every biologic maker has one), the MGFA, NORD, Patient Advocate Foundation, HealthWell Foundation, and state Medicaid programs. Prior authorization and appeals processes can be navigated with help from your care team. Asking for financial help early gives you the most options.

Clinical trials offer access to treatments not yet available to the public. The MG pipeline is exceptionally active, and trials are available for patients across all stages of the disease — from newly diagnosed to treatment-refractory. Trials are a recommended treatment option, not a last resort.

Ask your neurologist about trials at every visit. Your eligibility depends on your antibody type, severity, prior treatments, and other factors.
ClinicalTrials.gov — the U.S. National Library of Medicine maintains a registry of clinical trials worldwide. Search for "myasthenia gravis" and filter by location, status, and phase.
MGFA clinical trial resources — the MGFA maintains information about ongoing MG trials on their website.
In Utah: the University of Utah Neurosciences Center is the primary center for MG clinical trial access. Ask your neurologist for a referral if you are interested.
What to know: participating in a trial involves informed consent, regular monitoring, and potentially receiving a placebo (inactive treatment) for part of the study. All trials provide standard-of-care treatment as a baseline — you are not denied effective therapy.
Notable ongoing trials (as of 2026): Descartes-08 AURORA Phase 3 (mRNA CAR-T therapy), IMVT-1402 Phase 3 (next-gen FcRn inhibitor), NIMBLE (pozelimab + cemdisiran complement combination), RESET (rese-cel CD19 CAR-T), and others.

People with one autoimmune condition have a higher risk of developing others. MG commonly co-occurs with:

Thyroid disease (Hashimoto's thyroiditis, Graves' disease) — thyroid function should be checked at diagnosis and monitored periodically.
Rheumatoid arthritis
Systemic lupus erythematosus (SLE)
Type 1 diabetes
Pernicious anemia

If you have MG and develop new symptoms that do not fit your MG pattern (joint pain, rashes, unusual fatigue, weight changes), mention these to your neurologist — they may warrant screening for an additional autoimmune condition. Managing coexisting autoimmune conditions is important because they can affect your overall health and MG treatment choices.

Write your top 3–5 questions in advance — you will not remember them all otherwise.
Bring a current list of all medications (including supplements and over-the-counter drugs) with doses and times.
Bring someone with you, or ask to record the conversation.
Keep a personal folder of your key results: antibody type, MGFA Class, MG-ADL or QMG scores over time, thymoma status, and treatment history.
Note when you feel strongest and weakest during the day — this pattern helps your neurologist optimize your medication timing.
Ask for plain-language explanations — "Can you put that in everyday terms?" is always a fair question.

Daily symptom pattern — which muscles are weakest and when during the day
Pyridostigmine timing and effectiveness — how long after each dose do you feel strongest?
Swallowing difficulty (any coughing or choking during meals)
Speech changes (does your voice become nasal or weak during conversations?)
Breathing comfort, especially when lying flat or climbing stairs
Double vision episodes and eyelid drooping patterns
Fatigue levels throughout the day
Any new medications started by other doctors (check MG safety)
Side effects from your MG medications
Infections and fevers (report these early)

Modern MG biologics are among the most expensive drugs in medicine. Annual costs typically range from $300,000 to $500,000+ per year, and some complement inhibitors exceed $700,000 annually. This "financial toxicity" is a real and measurable barrier to treatment adherence and quality of life.

Patient assistance programs (PAPs)

Vyvgart (efgartigimod) — argenx CareConnect: Co-pay assistance, free drug programs for eligible uninsured/underinsured patients, and nurse support. Phone: 1-833-ARGENX1 (1-833-274-3691).
Rystiggo (rozanolixizumab) & Zilbrysq (zilucoplan) — UCB MyCares: Co-pay savings, patient assistance for eligible patients, and dedicated nurse case management. Phone: 1-844-599-2273.
Soliris (eculizumab) & Ultomiris (ravulizumab) — Alexion OneSource: Comprehensive support including co-pay assistance, free drug programs, and insurance navigation. Phone: 1-888-765-4747.
IMAAVY (nipocalimab) — J&J CarePath: Co-pay savings programs and patient assistance for eligible patients. Phone: 1-877-CarePath (1-877-227-3728).
UPLIZNA (inebilizumab) — Amgen Assist 360: Co-pay support and patient assistance programs. Phone: 1-888-427-7478.

Common insurance barriers

Prior authorization: required for virtually all MG biologics. Documentation typically needed: positive antibody test, MG-ADL score, failed prior therapies, MGFA class.
Step therapy ("fail first"): some insurers require documented failure of conventional immunosuppressants before approving biologics. Your neurologist can appeal with medical justification.
Medicare Part B vs. Part D: IV-administered biologics (Vyvgart IV, Soliris, Ultomiris, IMAAVY, UPLIZNA) are covered under Medicare Part B (medical benefit, typically 80% after deductible). Self-administered SC drugs (Vyvgart Hytrulo, Rystiggo, Zilbrysq) may fall under Part D (pharmacy benefit) with different cost-sharing.
Copay accumulator programs: some insurers no longer count manufacturer co-pay assistance toward your deductible or out-of-pocket maximum. Ask your insurance company specifically about this policy.

Additional financial resources

HealthWell Foundation — healthwellfoundation.org — co-pay assistance for eligible patients
Patient Advocate Foundation — patientadvocate.org — co-pay relief and insurance navigation
NORD Patient Assistance — rarediseases.org — programs for rare disease medications
MGFA Financial Resources — myasthenia.org — guidance on navigating MG treatment costs

Ask your neurology team's financial navigator or social worker early — before bills accumulate. Most academic medical centers and specialty pharmacies have dedicated staff to help navigate prior authorizations, appeals, and patient assistance programs. Asking for financial help early gives you the most options.

Most targeted MG biologics require prior authorization from your insurance company before they will be covered. This can be a frustrating process, but understanding it helps:

Prior authorization means your insurance requires your doctor to justify why you need this specific medication. Your neurology team will submit documentation of your diagnosis, severity scores, and previous treatments tried.
Step therapy ("fail first") — some insurers require you to try (and not respond to) older, cheaper medications before they will approve a biologic. Your doctor can sometimes appeal this with medical justification.
If denied, appeal. Initial denials are common and do not mean the medication is inappropriate for you. Your neurology team can submit an appeal with additional documentation. Most centers have staff experienced in this process.
Specialty pharmacy. Most MG biologics are dispensed through specialty pharmacies, not your local pharmacy. Your team will coordinate this.
Patient assistance programs. Every manufacturer of an MG biologic offers a patient assistance program for those who qualify financially. Ask about these early — do not wait until bills arrive.
Co-pay assistance. Foundations such as the HealthWell Foundation, Patient Advocate Foundation, and NORD may help with co-payments.

There is no specific "MG diet," but good nutrition supports your overall health and immune system:

If swallowing is difficult: work with a speech-language pathologist (speech therapist) who can assess your swallowing safety and recommend texture modifications. Softer foods, thicker liquids, smaller bites, and eating while sitting upright all help. Time meals when pyridostigmine is at peak effect (about 30–60 minutes after a dose).
If on prednisone: a diet lower in sodium, sugar, and refined carbohydrates can help manage weight gain, blood sugar, and fluid retention. Adequate calcium and vitamin D support bone health (steroids increase osteoporosis risk).
Potassium: low potassium can worsen muscle weakness. Eat potassium-rich foods (bananas, potatoes, leafy greens) unless your doctor advises otherwise.
Supplements: be cautious. Magnesium supplements can worsen MG in high doses. Always check with your neurologist before starting any supplement. There is no evidence that herbal or alternative supplements treat MG, and some may interact with MG medications.
Alcohol: alcohol can worsen fatigue and interact with MG medications. Use caution and discuss with your team.

DSHEA notice. Dietary supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA, 1994). Unlike prescription drugs, supplements are not evaluated by the FDA for safety or efficacy before they are sold. "Natural" does not mean "safe," especially for people with MG who take multiple medications. No supplement has been proven to treat or improve MG in rigorous clinical trials. Always inform your neurologist of all supplements you take.

For reference, here is the complete list of FDA-approved targeted therapies for generalized myasthenia gravis:

2017 Oct — Eculizumab (Soliris) — complement C5 inhibitor, AChR+ refractory gMG, IV every 2 weeks
2021 Dec — Efgartigimod (Vyvgart) — FcRn inhibitor, AChR+ gMG, IV treatment cycles; May 8, 2026: expanded to ALL adult gMG (all serotypes)
2022 Apr — Ravulizumab (Ultomiris) — complement C5 inhibitor, AChR+ gMG, IV every 8 weeks
2023 Jun — Efgartigimod SC (Vyvgart Hytrulo) — FcRn inhibitor, AChR+ gMG, SC treatment cycles
2023 Jun — Rozanolixizumab (Rystiggo) — FcRn inhibitor, AChR+ or MuSK+ gMG, SC treatment cycles
2023 Oct — Zilucoplan (Zilbrysq) — complement C5 inhibitor, AChR+ gMG, SC daily self-injection
2025 Feb — Eculizumab pediatric expansion (Feb 28, 2025) — complement C5, AChR+ gMG age 6+, IV every 2 weeks
2025 Apr — Nipocalimab (IMAAVY) — FcRn inhibitor, AChR+ and MuSK+ gMG, adults and age 12+, IV infusion only
2025 Dec — Inebilizumab (UPLIZNA) — anti-CD19 B-cell therapy, AChR+ and MuSK+ gMG, IV every 6 months

class="content-section" data-stage="resources">

Specialty Centers

Myasthenia gravis is best managed by neurologists with neuromuscular subspecialty training. If you are not already seeing a neuromuscular specialist, ask your primary care doctor or general neurologist for a referral. The following centers have established MG programs with expertise in biologic therapy, thymectomy, and clinical trial access.

University of Utah Neurosciences Center — Salt Lake City, UT. The primary Utah center for MG specialist care, with fellowship-trained neuromuscular neurologists (Dr. Kyle W. Mahoney, MD; Dr. Tammy Smith, MD, PhD), comprehensive electrodiagnostic laboratory (RNS, SFEMG), ARUP Laboratories consultation hub for cell-based autoantibody assays, infusion center for IVIG and all FDA-approved MG biologics, and clinical trial access. Active MINT trial site (NCT04524273). (801) 585-7575
University of Utah Health — Thoracic Surgery — Salt Lake City, UT. Referral center for thymectomy, including robotic-assisted and VATS approaches.
Intermountain Health Neurosciences — Murray and locations across the Wasatch Front. MG diagnosis and management with established referral pathways to the University of Utah for refractory or complex cases and biologic therapy.
University of Colorado — Neuromuscular Medicine — Aurora, CO. Academic neuromuscular program with MG expertise and clinical trial participation.

Duke University — Neuromuscular Disease Center — Durham, NC. Major academic center for MG care and research, with a dedicated MG clinic and extensive clinical trial portfolio. (919) 684-5005
Johns Hopkins — Neuromuscular Medicine — Baltimore, MD. One of the leading neuromuscular programs in the country with MG-specialized neurologists and clinical trials. (410) 955-9441
Yale — Myasthenia Gravis Clinic — New Haven, CT. Dedicated MG clinic led by investigators involved in multiple landmark MG biologic trials. (203) 785-4085
Massachusetts General Hospital — Neuromuscular Center — Boston, MA. Comprehensive MG program with expertise in complex and refractory cases. (617) 726-3642
University of North Carolina — Neuromuscular Disorders Center — Chapel Hill, NC. Academic MG program with clinical trial access and subspecialty expertise.

VA Salt Lake City Health Care System — Salt Lake City, UT. Neurology service with MG management; can coordinate referrals to University of Utah for subspecialty care and biologic therapy. (801) 582-1565
VA Ann Arbor Healthcare System — Ann Arbor, MI. Neuromuscular program affiliated with the University of Michigan.
Durham VA Health Care System — Durham, NC. Affiliated with Duke University; access to neuromuscular subspecialty care and clinical trials.
VA Boston Healthcare System — Boston, MA. Neurology service with referral access to Massachusetts General Hospital and Brigham neuromuscular programs.

All VA medical centers can coordinate referrals to VA centers of excellence or academic affiliates for complex MG management and biologic therapy. Ask your VA neurologist about the Community Care program if local expertise is limited.

University of Toronto — Ellen and Martin Prosserman Centre for Neuromuscular Diseases — Toronto, ON. One of Canada’s largest neuromuscular programs with MG subspecialty expertise.
Montreal Neurological Institute-Hospital (The Neuro) — Montreal, QC. Leading Canadian center for neuromuscular disorders with MG research programs.
University of British Columbia — Neuromuscular Disease Unit — Vancouver, BC. Academic MG program with clinical trial participation.
University of Alberta — Neuromuscular Clinic — Edmonton, AB. Regional referral center for neuromuscular disorders including MG.

University of Oxford — Neuromuscular Centre — Oxford, UK. Leading MG research center with contributions to MuSK-MG understanding and biologic trials.
Leiden University Medical Center — Leiden, Netherlands. Major European neuromuscular center with MG research expertise.
Chiba University Hospital — Chiba, Japan. Academic MG program; Japan is at the forefront of tacrolimus use in MG and early thymectomy approaches.
Charité — Universitätsmedizin Berlin — Berlin, Germany. Leading European center for neuromuscular diseases with MG specialty care and clinical trials.
Royal Prince Alfred Hospital — Sydney, Australia. Major Australian neuromuscular center with MG subspecialty expertise.

AChR (acetylcholine receptor) — the receptor on muscle cells that receives signals from nerves. The main target of autoimmune attack in most MG patients.
MuSK (muscle-specific kinase) — a protein that maintains the structure of the neuromuscular junction. The target in MuSK-positive MG.
LRP4 (low-density lipoprotein receptor-related protein 4) — another protein at the neuromuscular junction targeted by antibodies in a small subset (~1–2%) of MG patients. Testing is not widely available outside research settings.
FcRn (neonatal Fc receptor) — a receptor that recycles IgG antibodies, keeping them in the blood longer. FcRn inhibitors block this recycling to reduce harmful antibodies.
Complement (C5) — part of the innate immune system that can damage the neuromuscular junction in AChR-positive MG. Complement inhibitors block this damage.
MGFA Classification — the Myasthenia Gravis Foundation of America classification of disease severity (Class I through V).
Osserman Classification — an older classification system for MG severity. Largely replaced by the MGFA system in clinical practice, but still referenced in some older literature.
MG-ADL — an 8-item patient-reported questionnaire measuring how MG affects daily activities. Used to track treatment response.
QMG (Quantitative MG score) — a 13-item clinician-scored examination measuring muscle strength in specific groups.
MG Composite — a 10-item combined patient-clinician assessment of MG severity, increasingly used in clinical trials.
Minimal manifestation status — the treatment goal — having no or minimal symptoms that do not limit function.
Steroid-sparing — reducing or eliminating the need for corticosteroids (prednisone).
Myasthenic crisis — life-threatening worsening of MG requiring ICU care and often mechanical ventilation.
PLEX (plasma exchange / plasmapheresis) — a procedure that removes harmful antibodies from the blood.
IVIG (intravenous immunoglobulin) — pooled antibodies given by IV to modulate the immune system.
REMS (Risk Evaluation and Mitigation Strategy) — an FDA-required safety program for high-risk medications. All complement inhibitors for MG require REMS enrollment for prescribers, pharmacies, and patients.
Thymectomy — surgical removal of the thymus gland.
Thymoma — a tumor of the thymus gland, found in about 10–15% of MG patients.
Ptosis — drooping of the eyelid.
Diplopia — double vision.
Bulbar symptoms — difficulty swallowing, speaking, or chewing (related to muscles controlled by cranial nerves).
Cholinergic crisis — overmedication with pyridostigmine causing excessive acetylcholine. Symptoms overlap with myasthenic crisis (weakness, respiratory difficulty) but also include excessive salivation, tearing, urination, and diarrhea. Distinguishing from myasthenic crisis requires medical evaluation.
Secondary generalization — progression from ocular-only MG (Class I) to generalized MG (Class II+), occurring in 30–50% of ocular MG patients within the first two years.

Sources & Key References

This guide synthesizes information from the following primary sources. All claims have been cross-referenced against published evidence. Links are provided where available.

Guidelines

Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. PMID 27358333
Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122. PMID 33144515
National Institute for Health and Care Excellence (NICE). Myasthenia gravis [NG237]. 2024. nice.org.uk/guidance/ng237

Landmark trials

Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis (MGTX). N Engl J Med. 2016;375(6):511-522. PMID 27509100. NCT00294658
Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). Lancet Neurol. 2021;20(7):526-536. PMID 34146511. NCT03669588
Howard JF Jr, et al. Zilucoplan in acetylcholine receptor antibody-positive generalized myasthenia gravis (RAISE). Lancet Neurol. 2023;22(5):395-406. PMID 37059508. NCT04115293
Vu T, Meisel A, Bhatt P, et al. Ravulizumab in myasthenia gravis (CHAMPION-MG). NEJM Evid. 2022;1(5):EVIDoa2100066. PMID 38319212. NCT03920293
Bril V, et al. Rozanolixizumab in myasthenia gravis (MycarinG). Lancet Neurol. 2023;22(5):383-394. PMID 37059507. NCT03971422
Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN). Lancet Neurol. 2017;16(12):976-986. PMID 29066163. NCT01997229
Piehl F, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis (RINOMAX). JAMA Neurol. 2022;79(11):1105-1112. PMID 36121672. NCT02950155

FDA labels & prescribing information

Vyvgart (efgartigimod alfa-fcab) — FDA Label
Soliris (eculizumab) — FDA Label
Ultomiris (ravulizumab-cwvz) — FDA Label
Zilbrysq (zilucoplan) — FDA Label
Rystiggo (rozanolixizumab-ulbb) — FDA Label
IMAAVY (nipocalimab-ibrl) — FDA Label (2025)
UPLIZNA (inebilizumab-cdon) — FDA Label (2025 supplemental for MG)

Key reviews & additional sources

Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. PMID 31048702
Muppidi S, Wolfe GI. Myasthenia Gravis: Treatment Considerations. Continuum (Minneap Minn). 2022;28(6):1720-1744.
ClinicalTrials.gov (clinicaltrials.gov) — US National Library of Medicine
Myasthenia Gravis Foundation of America (myasthenia.org)

Databases & registries consulted

NINDS (National Institute of Neurological Disorders and Stroke) — Myasthenia Gravis Fact Sheet. ninds.nih.gov
GARD (Genetic and Rare Diseases Information Center) — NIH-supported rare disease information. rarediseases.info.nih.gov
LiverTox (NIDDK) — Drug-induced liver injury information for MG immunosuppressants. livertox.nih.gov
LactMed (NLM) — Drugs and lactation database for MG medications in breastfeeding. lactmed.nlm.nih.gov
Orphanet — European rare disease database. orpha.net
EURORDIS (European Organisation for Rare Diseases) — Patient advocacy and resource network. eurordis.org
PharmGKB — Pharmacogenomics knowledge base for gene-drug interactions relevant to MG therapy. pharmgkb.org
AWMF (Association of the Scientific Medical Societies in Germany) — German clinical practice guidelines for MG. awmf.org
Cochrane Neuromuscular Group — Systematic reviews of MG interventions. neuromuscular.cochrane.org
WHO ICTRP (International Clinical Trials Registry Platform) — Global clinical trial registry. who.int/clinical-trials-registry-platform

Important disclaimer. This guide is for general education only and does not constitute medical advice, diagnosis, or treatment. Myasthenia gravis care is highly individual and the evidence is evolving rapidly — drug approvals, guidelines, and access can change. Always rely on your own neurologist or neuromuscular specialist, who knows your specific situation, for decisions about your care. Brand names are listed for recognition only and do not imply endorsement. If you are experiencing worsening breathing, swallowing, or speaking difficulty, seek emergency medical care immediately. Many common medications can dangerously worsen MG — always carry a medication alert card and inform all healthcare providers of your MG diagnosis.